<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">85023</article-id><article-id pub-id-type="doi">10.7554/eLife.85023</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Evolutionary Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Diverse evolutionary pathways challenge the use of collateral sensitivity as a strategy to suppress resistance</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-299030"><name><surname>Mandt</surname><given-names>Rebecca EK</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7165-7876</contrib-id><email>rebeccamandt@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-299919"><name><surname>Luth</surname><given-names>Madeline R</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-300138"><name><surname>Tye</surname><given-names>Mark A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-300139"><name><surname>Mazitschek</surname><given-names>Ralph</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-300140"><name><surname>Ottilie</surname><given-names>Sabine</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-300141"><name><surname>Winzeler</surname><given-names>Elizabeth A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4049-2113</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-299922"><name><surname>Lafuente-Monasterio</surname><given-names>Maria Jose</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-299923"><name><surname>Gamo</surname><given-names>Francisco Javier</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-17172"><name><surname>Wirth</surname><given-names>Dyann F</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" corresp="yes" id="author-272487"><name><surname>Lukens</surname><given-names>Amanda K</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9560-7643</contrib-id><email>alukens@broadinstitute.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution>Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0168r3w48</institution-id><institution>Division of Host Pathogen Systems and Therapeutics, Department of Pediatrics, University of California, San Diego</institution></institution-wrap><addr-line><named-content content-type="city">San Diego</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Center for Systems Biology, Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Harvard Graduate School of Arts and Sciences</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0168r3w48</institution-id><institution>Skaggs School of Pharmaceutical Sciences, University of California, San Diego</institution></institution-wrap><addr-line><named-content content-type="city">La Jolla</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Tres Cantos Medicines Development Campus, Diseases of the Developing World, GlaxoSmithKline</institution><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05a0ya142</institution-id><institution>Infectious Disease and Microbiome Program, The Broad Institute</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Clayton</surname><given-names>Christine</given-names></name><role>Reviewing Editor</role><aff><institution>Centre for Molecular Biology of Heidelberg University (ZMBH), retired</institution><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Soldati-Favre</surname><given-names>Dominique</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01swzsf04</institution-id><institution>University of Geneva</institution></institution-wrap><country>Switzerland</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>22</day><month>09</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e85023</elocation-id><history><date date-type="received" iso-8601-date="2022-11-18"><day>18</day><month>11</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-09-21"><day>21</day><month>09</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-04-07"><day>07</day><month>04</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.04.07.486819"/></event></pub-history><permissions><copyright-statement>© 2023, Mandt et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Mandt et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-85023-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-85023-figures-v2.pdf"/><abstract><p>Drug resistance remains a major obstacle to malaria control and eradication efforts, necessitating the development of novel therapeutic strategies to treat this disease. Drug combinations based on collateral sensitivity, wherein resistance to one drug causes increased sensitivity to the partner drug, have been proposed as an evolutionary strategy to suppress the emergence of resistance in pathogen populations. In this study, we explore collateral sensitivity between compounds targeting the <italic>Plasmodium</italic> dihydroorotate dehydrogenase (DHODH). We profiled the cross-resistance and collateral sensitivity phenotypes of several DHODH mutant lines to a diverse panel of DHODH inhibitors. We focus on one compound, TCMDC-125334, which was active against all mutant lines tested, including the DHODH C276Y line, which arose in selections with the clinical candidate DSM265. In six selections with TCMDC-125334, the most common mechanism of resistance to this compound was copy number variation of the <italic>dhodh</italic> locus, although we did identify one mutation, DHODH I263S, which conferred resistance to TCMDC-125334 but not DSM265. We found that selection of the DHODH C276Y mutant with TCMDC-125334 yielded additional genetic changes in the <italic>dhodh</italic> locus. These double mutant parasites exhibited decreased sensitivity to TCMDC-125334 and were highly resistant to DSM265. Finally, we tested whether collateral sensitivity could be exploited to suppress the emergence of resistance in the context of combination treatment by exposing wildtype parasites to both DSM265 and TCMDC-125334 simultaneously. This selected for parasites with a DHODH V532A mutation which were cross-resistant to both compounds and were as fit as the wildtype parent in vitro. The emergence of these cross-resistant, evolutionarily fit parasites highlights the mutational flexibility of the DHODH enzyme.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>Malaria affects around 240 million people around the world every year. The microscopic parasite responsible for the disease are carried by certain mosquitoes and gets transmitted to humans through bites. These parasites are increasingly acquiring genetic mutations that make anti-malaria medication less effective, creating an urgent need for alternative treatment approaches.</p><p>Several new malaria drugs being explored in preclinical research work by binding to an enzyme known as DHODH and preventing it from performing its usual role in the parasite. Previous work found that, in some cases, malaria parasites that evolved resistance to one type of DHODH inhibitor (by acquiring mutations in their DHODH enzyme) then became more vulnerable to another kind. It may be possible to leverage this ‘collateral sensitivity’ by designing treatments which combine two DHODH inhibitors and therefore make it harder for the parasites to evolve resistance.</p><p>To investigate this possibility, Mandt et al. first tested several DHODH inhibitors to find the one that was most potent against drug-resistant parasites. In subsequent experiments, they combined TCMDC-125334, the best candidate that emerged from these tests, with a DHODH inhibitor that works well against vulnerable parasites. However, the parasites still rapidly evolved resistance. Further work identified a new DHODH mutation that allowed the parasites to evade both drugs simultaneously.</p><p>Together, these findings suggest that the DHODH enzyme may not be the best target for new malaria drugs because many it can acquire many possible mutations that confer resistance. Such results may inform other studies that aim to harness collateral sensitivity to fight against a range of harmful agents.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>malaria</kwd><kwd>drug resistance</kwd><kwd><italic>Plasmodium falciparum</italic></kwd><kwd>dihydroorotate dehydrogenase</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>P. falciparum</italic></kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 AI093716</award-id><principal-award-recipient><name><surname>Mandt</surname><given-names>Rebecca EK</given-names></name><name><surname>Wirth</surname><given-names>Dyann F</given-names></name><name><surname>Lukens</surname><given-names>Amanda K</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000865</institution-id><institution>Bill and Melinda Gates Foundation</institution></institution-wrap></funding-source><award-id>OPP1132451</award-id><principal-award-recipient><name><surname>Mandt</surname><given-names>Rebecca EK</given-names></name><name><surname>Lafuente-Monasterio</surname><given-names>Maria Jose</given-names></name><name><surname>Gamo</surname><given-names>Francisco Javier</given-names></name><name><surname>Wirth</surname><given-names>Dyann F</given-names></name><name><surname>Lukens</surname><given-names>Amanda K</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32 GM008666</award-id><principal-award-recipient><name><surname>Luth</surname><given-names>Madeline R</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100012640</institution-id><institution>ExxonMobil Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Mandt</surname><given-names>Rebecca EK</given-names></name><name><surname>Wirth</surname><given-names>Dyann F</given-names></name><name><surname>Lukens</surname><given-names>Amanda K</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 AI169892</award-id><principal-award-recipient><name><surname>Lukens</surname><given-names>Amanda K</given-names></name><name><surname>Wirth</surname><given-names>Dyann F</given-names></name><name><surname>Winzeler</surname><given-names>Elizabeth A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The mutational flexibility of the antimalarial target dihydroorotate dehydrogenase thwarts the use of collateral sensitivity as a strategy to suppress the evolution of resistance.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Antimicrobial resistance threatens our ability to combat multiple infectious agents, and is widely recognized as one of the greatest public health threats of the 21st century (<xref ref-type="bibr" rid="bib31">Jee et al., 2018</xref>). Globally, drug resistance is a recurring obstacle in efforts to control many endemic infectious diseases, and malaria is no exception. The emergence of resistance in <italic>Plasmodium</italic> parasite populations and subsequent treatment failure has been documented for all antimalarial drugs in clinical use, including frontline artemisinin combination therapies (<xref ref-type="bibr" rid="bib25">Haldar et al., 2018</xref>). Thus, there is an ongoing need to develop a next generation of drugs targeting distinct vulnerabilities of <italic>Plasmodium</italic> parasites.</p><p>Additionally, understanding the pathways and susceptibility to drug resistance is important to assess next-generation antimalarials, ideally while they are still early in the development process. Inhibitors targeting the <italic>Plasmodium</italic> dihydroorotate dehydrogenase (DHODH) offer an illustrative example. DHODH is an electron transport chain protein that catalyzes the oxidation of dihydroorotate in orotic acid, which is the rate-limiting step of pyrimidine biosynthesis. In <italic>Plasmodium,</italic> this reaction is dependent on flavin mononucleotide and ubiquinone cofactors and is coupled to mitochondrial respiration. Because <italic>Plasmodium</italic> lacks pyrimidine scavenging pathways, this enzyme is essential for parasite growth and survival (<xref ref-type="bibr" rid="bib57">Phillips and Rathod, 2010</xref>). Multiple high-throughput screens have identified DHODH as a drug target in <italic>Plasmodium falciparum</italic> (<xref ref-type="bibr" rid="bib2">Baldwin et al., 2005</xref>; <xref ref-type="bibr" rid="bib55">Pavadai et al., 2016</xref>; <xref ref-type="bibr" rid="bib54">Patel et al., 2008</xref>; <xref ref-type="bibr" rid="bib64">Ross et al., 2018</xref>; <xref ref-type="bibr" rid="bib56">Phillips et al., 2008</xref>), and the triazolopyrimidine-based DHODH inhibitor DSM265 was developed as a clinical antimalarial candidate (<xref ref-type="bibr" rid="bib58">Phillips et al., 2015</xref>).</p><p>While the clinical DHODH inhibitor candidate DSM265 showed promising activity in pre-clinical and clinical studies (<xref ref-type="bibr" rid="bib40">Llanos-Cuentas et al., 2018</xref>; <xref ref-type="bibr" rid="bib49">McCarthy et al., 2017</xref>; <xref ref-type="bibr" rid="bib51">Murphy et al., 2018</xref>; <xref ref-type="bibr" rid="bib58">Phillips et al., 2015</xref>; <xref ref-type="bibr" rid="bib70">Sulyok et al., 2017</xref>), we previously demonstrated that resistance to DSM265 emerges rapidly both in vitro and in a humanized mouse model of <italic>P. falciparum</italic> infection (<xref ref-type="bibr" rid="bib47">Mandt et al., 2019</xref>). Resistance was primarily conferred by point mutations in the <italic>dhodh</italic> locus. In Phase 2 clinical trials with DSM265, 2 out of 24 patients failed treatment due to resistance, with recrudescent parasites harboring mutations in <italic>dhodh</italic> including DHODH C276Y, C276F, and G181S (<xref ref-type="bibr" rid="bib40">Llanos-Cuentas et al., 2018</xref>). The C276Y and C276F mutations were also observed in in vitro resistance selections, as was DHODH G181C (<xref ref-type="bibr" rid="bib58">Phillips et al., 2015</xref>; <xref ref-type="bibr" rid="bib47">Mandt et al., 2019</xref>; <xref ref-type="bibr" rid="bib71">White et al., 2019</xref>). The point mutations C276F and G181D were observed in our in vivo selection model (<xref ref-type="bibr" rid="bib47">Mandt et al., 2019</xref>).</p><p>A common strategy to counter the evolution of resistance is to utilize a combination of two or more drugs with distinct antimicrobial mechanisms. The basic rationale for this strategy is that even if there is some probability of an organism acquiring resistance to each drug separately, the probability that two resistance mutations would occur simultaneously is much lower. Combination therapy is the standard of treatment for malaria (<xref ref-type="bibr" rid="bib27">Hastings, 2011</xref>), tuberculosis (<xref ref-type="bibr" rid="bib35">Kerantzas and Jacobs, 2017</xref>), and HIV/AIDS (<xref ref-type="bibr" rid="bib9">Cihlar and Fordyce, 2016</xref>), and is increasingly being recommended for the treatment of other bacterial infections (<xref ref-type="bibr" rid="bib65">Schmid et al., 2019</xref>; <xref ref-type="bibr" rid="bib10">Coates et al., 2020</xref>; <xref ref-type="bibr" rid="bib5">Bodie et al., 2019</xref>). However, multidrug resistance has emerged in many major human pathogens, complicating patient treatment and threatening public health efforts to control the spread of disease (<xref ref-type="bibr" rid="bib26">Hamilton et al., 2019</xref>; <xref ref-type="bibr" rid="bib48">Manson et al., 2017</xref>; <xref ref-type="bibr" rid="bib16">Dheda et al., 2017</xref>; <xref ref-type="bibr" rid="bib23">Gregson et al., 2017</xref>). Large-scale bacterial evolution studies have also shown that certain combinations of inhibitors can actually accelerate the emergence of resistance compared to treatment with a single inhibitor (<xref ref-type="bibr" rid="bib28">Hegreness et al., 2008</xref>; <xref ref-type="bibr" rid="bib13">Dean et al., 2020</xref>). Thus, there is a need to re-evaluate the current treatment approach, and to strategically design combination therapies based on their ability to slow or suppress the emergence of resistance.</p><p>One possible strategy takes advantage of collateral sensitivity, in which resistance to one drug causes increased sensitivity to another (<xref ref-type="bibr" rid="bib4">Baym et al., 2016</xref>). The phenomenon of collateral sensitivity, or ‘negative cross-resistance’, has been observed across various antibiotic classes in bacteria, as well as anti-fungals, and even cancer therapies (<xref ref-type="bibr" rid="bib30">Imamovic and Sommer, 2013</xref>; <xref ref-type="bibr" rid="bib62">Rosenkilde et al., 2019</xref>; <xref ref-type="bibr" rid="bib45">Maltas and Wood, 2019</xref>; <xref ref-type="bibr" rid="bib59">Rank et al., 1975</xref>; <xref ref-type="bibr" rid="bib39">Leroux et al., 2000</xref>; <xref ref-type="bibr" rid="bib15">Dhawan et al., 2017</xref>; <xref ref-type="bibr" rid="bib41">Lorendeau et al., 2017</xref>). Laboratory studies evaluating the evolution of resistance to antibiotics have demonstrated that when resistance to one inhibitor leads to collateral sensitivity to another, the two inhibitors can be used in a sequential cycling strategy to maintain sensitive bacterial populations (<xref ref-type="bibr" rid="bib30">Imamovic and Sommer, 2013</xref>; <xref ref-type="bibr" rid="bib36">Kim et al., 2014</xref>), or simultaneously in combination to slow or suppress the evolution of resistance (<xref ref-type="bibr" rid="bib22">Gonzales et al., 2015</xref>; <xref ref-type="bibr" rid="bib50">Munck et al., 2014</xref>; <xref ref-type="bibr" rid="bib61">Rodriguez de Evgrafov et al., 2015</xref>).</p><p>Collateral sensitivity to various classes of inhibitors targeting <italic>Plasmodium</italic> parasites has also been observed. For example, isoforms of the chloroquine resistance transporter (<italic>Pf</italic>CRT) that transport chloroquine out of the parasite’s digestive vacuole can cause increased sensitivity to a variety of compounds (<xref ref-type="bibr" rid="bib43">Lukens et al., 2014</xref>; <xref ref-type="bibr" rid="bib33">Johnson et al., 2004</xref>; <xref ref-type="bibr" rid="bib66">Sisowath et al., 2009</xref>; <xref ref-type="bibr" rid="bib60">Richards et al., 2016</xref>; <xref ref-type="bibr" rid="bib11">Cooper et al., 2002</xref>; <xref ref-type="bibr" rid="bib19">Evans and Havlik, 1993</xref>; <xref ref-type="bibr" rid="bib67">Small-Saunders et al., 2022</xref>). Collateral sensitivity has also been observed between compounds targeting different subunits of the <italic>Plasmodium</italic> proteasome <italic>Pf</italic>20S (<xref ref-type="bibr" rid="bib37">Kirkman et al., 2018</xref>; <xref ref-type="bibr" rid="bib69">Stokes et al., 2019</xref>), between different chemotypes targeting the P-Type Cation-Transporter ATPase 4 (<italic>Pf</italic>ATP4) (<xref ref-type="bibr" rid="bib20">Flannery et al., 2015</xref>), and between compounds targeting the Q<sub>o</sub> and Q<sub>i</sub> sites of cytochrome b (<xref ref-type="bibr" rid="bib44">Lukens et al., 2015</xref>). We have also previously shown that collateral sensitivity occurs during the evolution of resistance to <italic>Plasmodium</italic> DHODH inhibitors. Mutations in <italic>dhodh</italic> conferring resistance to one inhibitor can alter the enzyme such that it becomes more sensitive to inhibition by other, structurally distinct compounds (<xref ref-type="bibr" rid="bib43">Lukens et al., 2014</xref>; <xref ref-type="bibr" rid="bib63">Ross et al., 2014</xref>). The existence of collateral sensitivity among a wide range of antimalarial inhibitors suggests a promising opportunity to exploit this phenomenon to block the emergence of resistant parasites (<xref ref-type="bibr" rid="bib43">Lukens et al., 2014</xref>).</p><p>In an effort to expand this work, we screened antimalarial libraries from GSK, and successfully identified several compounds with increased activities against DHODH mutants relative to wildtype parasites (<xref ref-type="bibr" rid="bib64">Ross et al., 2018</xref>). In this study, we test the hypothesis that combining two DHODH inhibitors based on their collateral sensitivity profiles would suppress the emergence of resistant parasites. We focused on the compound TCMDC-125334, a DHODH inhibitor that exhibited increased activity against all mutant lines tested, including those that arose during selection with the clinical candidate DSM265. We used in vitro resistance selections to characterize the pathways to resistance for TCMDC-125334 and then tested whether parasites develop resistance in the context of combined treatment with DSM265 and TCMDC-125334.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>TCMDC-125334 demonstrates activity against all DHODH mutant parasite lines tested</title><p>Previously, we screened GSK chemical libraries from the Tres Cantos Antimalarial Set for activity against either wildtype or DHODH mutant parasites (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>; <xref ref-type="bibr" rid="bib64">Ross et al., 2018</xref>). In an extended cross-resistance analysis, we characterized the activity of 17 compounds against three additional DHODH mutant lines, DHODH C276Y, DHODH F227L, and DHODH F227L/L531F (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). We visualized the log-transformed fold change in EC<sub>50</sub> of each mutant relative to its parental line on a heatmap (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Hierarchical clustering of this data reveals broad patterns of cross-resistance and collateral sensitivity. The DHODH C276Y, F227I, F227I/L527I, F227L, and F227L/L31F mutant lines have similar dose-response phenotypes. The DHODH E182D and I263F mutant lines also share similar cross-resistance profiles, as we previously reported (<xref ref-type="bibr" rid="bib64">Ross et al., 2018</xref>). In contrast, the DHODH L531F mutant line has a unique sensitivity phenotype (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). This analysis also suggests some structure-activity relationships. Five related triazolopyrimidine-based compounds (DSM265, DSM267, TCMDC-124402, TCMDC-124417, TCMDC-123826) cluster together, as all mutant lines show cross-resistance against these molecules (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). TCMDC-123823, TCMDC-123545, and TCMDC-123566 also cluster together based on their activity profile, and have a similar chemical structure (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). We had previously reported that the compound TCMDC-125334 was active against the DHODH E182E, I263F, F227I, and F227I/L527I lines (<xref ref-type="bibr" rid="bib64">Ross et al., 2018</xref>). In our extended cross-resistance analysis, we showed that TCMDC-125334 is also active against the DHODH C276Y, F227L, and F227L/L531F lines. The eight mutant lines had varying degrees of sensitivity to this compound, from DHODH I263F which is 1.3-fold more sensitive than the wildtype parent, to DHODH C276Y, which is 12-fold sensitive. In contrast, all mutant lines were at least 10-fold resistant to DSM265 (<xref ref-type="fig" rid="fig1">Figure 1C</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Identifying DHODH inhibitors with broad activity against mutant lines.</title><p>We tested several DSM265-resistant parasite lines against a set of 17 compounds identified from a previous screen of GSK libraries (<xref ref-type="bibr" rid="bib64">Ross et al., 2018</xref>). (<bold>A</bold>) Crystal structure of DHODH bound to DSM265 (PDB ID: 4<italic>R</italic>X0). Mutations included in our cross-resistance analysis are highlighted in pink. (<bold>B</bold>) To visualize patterns of cross-resistance and collateral sensitivity, we calculated the fold change of each mutant line over its wildtype parent, and plotted the log<sub>10</sub>-transformed values in a heatmap. Hierarchical clustering by Euclidean distance based on both parasite line and compound was performed using MultiExperimentViewer v4.9. Shades of red indicate that a parasite line is resistant to the indicated compound while blue indicates that it is sensitive. The DHODH C276Y, F227L, and F227L/L531F are newly reported, while other mutant lines were reported in our previous cross-resistance analysis (<xref ref-type="bibr" rid="bib64">Ross et al., 2018</xref>). The wildtype parent for the DHODH F227I, L531F, F227I/L527I, and I263F lines is Dd2. The wildtype parent for the DHODH E182D line is 3D7. The wildtype parent for the DHODH C276Y, F227L, and F227L/L531F lines is 3D7 A10. (<bold>C</bold>) One compound, TCMDC-125334 stands out in this analysis as being active against all mutant lines tested. Shown is a bar graph of the log<sub>10</sub> fold change in EC<sub>50</sub> relative to wildtype for all eight mutant lines tested against DSM265 and TCMDC-125334. DSM265 data was previously reported (<xref ref-type="bibr" rid="bib47">Mandt et al., 2019</xref>). Each dose-response assay was performed with triplicate technical replicates, and average EC<sub>50</sub>’s were obtained from 4 to 5 independent biological replicates. See also <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Individual bioreplicates of EC<sub>50</sub> values (nM) obtained from dose-response assays.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85023-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85023-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Hierarchical clustering tree of mutant lines and compounds.</title><p>Clustering was done using Euclidean distance and average linkage clustering. Data was analyzed and image produced by MultiExperimentViewer (MeV) v. 4.9.0.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85023-fig1-figsupp1-v2.tif"/></fig></fig-group><p>While none of the mutations in <italic>dhodh</italic> conferred resistance to TCMDC-125334, we previously reported that this compound appears to exclusively target the DHODH enzyme. Expression of the <italic>Saccharomyces cerevisiae</italic> cytosolic type I DHODH (<italic>Sc</italic>DHODH) bypasses the mitochondrial DHODH enzyme, rendering blood-stage parasites insensitive to inhibitors that target electron transport chain proteins DHODH and cytochrome bc1. However, addition of proguanil has a potentiating effect for compounds that target cytochrome bc1, but not DHODH (<xref ref-type="bibr" rid="bib53">Painter et al., 2007</xref>). We previously confirmed that expression of <italic>Sc</italic>DHODH ablates the activity of TCMDC-125334, and that treating the <italic>Sc</italic>DHODH line with TCMDC-125334 and proguanil in combination does not impact this activity (<xref ref-type="bibr" rid="bib64">Ross et al., 2018</xref>; <xref ref-type="bibr" rid="bib17">Dong et al., 2011</xref>).</p></sec><sec id="s2-2"><title>Resistance to TCMDC-125334 can be conferred by copy number variation as well as the novel point mutation DHODH I263S</title><p>Since TCMDC-125334 showed activity against all DHODH mutant lines tested, we wanted to characterize the evolution of resistance to this compound to determine its independent ability to select resistant mutants. We performed in vitro selections with three independent populations of 10<sup>8</sup> <italic>Pf</italic>3D7 A10 parasites (<xref ref-type="bibr" rid="bib12">Cowell et al., 2018</xref>). Cultures were treated with 830 nM TCMDC-125334 (approximately the EC<sub>99</sub>) until no living parasites were visible by thin smear microscopy, then allowed to recover in compound-free media. After two rounds of treatment, populations displayed moderate (~2-fold) resistance to TCMDC-125334 (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). Selected parasites were cloned by limiting dilution. Clonal lines isolated from flask 1 had two- or threefold copy number variation (CNV) encompassing the <italic>dhodh</italic> locus, which corresponded to a two- or three-fold resistance phenotype to TCMDC-125334, as well as to the structurally distinct DHODH inhibitors DSM265, Genz669178, and IDI6273. Of the clones isolated from flask 2, four did not have a resistance phenotype, and had no genetic changes in the <italic>dhodh</italic> locus (<xref ref-type="fig" rid="fig2">Figure 2C–F</xref>, <xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="table1sdata1">Table 1—source data 1</xref>, <xref ref-type="supplementary-material" rid="table1sdata2">Table 1—source data 2</xref>, <xref ref-type="supplementary-material" rid="table1sdata3">Table 1—source data 3</xref>). One clone, T-F2-C1, was 3-fold resistant to TCMDC-125334 and Genz669178, and 13-fold resistant to IDI-6273 (<xref ref-type="fig" rid="fig2">Figure 2C–F</xref>, <xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="supplementary-material" rid="table1sdata1">Table 1—source data 1</xref>). Whole-genome sequencing (WGS) revealed that clone T-F2-C1 had a point mutation resulting in a DHODH I263S amino acid change (<xref ref-type="supplementary-material" rid="table1sdata3">Table 1—source data 3</xref>). Notably, this DHODH I263S parasite line remained sensitive to DSM265 (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, <xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="supplementary-material" rid="table1sdata1">Table 1—source data 1</xref>). (Note that <xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="table" rid="table1">Table 1</xref> show two representative clones from each flask. See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref> for a list of all isolated parasite clones.)</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>In vitro resistance to TCMDC125334 can be mediated by copy number variation as well as the novel point mutation DHODH I263S.</title><p>(<bold>A</bold>) Protocol for in vitro selection with TCMDC-125334. Parasite populations in three independent 25 mL culture flasks were exposed to 830 nM TCMDC-125334, then allowed to recover in the absence of compound. Resistant parasites emerged after two rounds of treatment within the indicated timeframe. (<bold>B</bold>) In vitro dose-response curve of bulk populations recovered after the second pulse of compound treatment. Error bars show standard deviation of three technical replicates. (<bold>C–E</bold>) Resistant populations were cloned by limiting dilutions. Shown are the average EC<sub>50</sub> and standard deviation for three biological replicates of dose-response phenotype of two representative clones from each flask for TCMDC-125334 (<bold>C</bold>), DSM265 (<bold>D</bold>), Genz669178 (<bold>E</bold>), and IDI-6273 (<bold>F</bold>). Each dose-response assay was performed with triplicate technical replicates, and average EC<sub>50</sub>’s were obtained from 3 to 4 independent biological replicates. Compound structures for TCMDC-125334, DSM265, Genz669178, and IDI-6273 are displayed below their corresponding graphs. The parasite lines are each designated with a unique identifier; for example, T-F1-C1 was selected with TCDC-125334 (T) came from flask 1 (F1), and is designated as ‘C1’ for ‘Clone 1’. DHODH genotypes for representative clones are as follows: T-F1-C1: 2x <italic>dhodh</italic> copy number variation (CNV); T-F1-C2: 3x <italic>dhodh</italic> CNV; T-F2-C1: DHODH I263F; T-F2-C1: WT. Statistical significance was determined by a Kruskal-Wallis test, with post hoc multiple comparisons (Dunn’s) of each clone to 3D7 A10. *p≤0.05; **p≤0.01. See also <xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>, and <xref ref-type="supplementary-material" rid="table1sdata1">Table 1—source data 1</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85023-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Copy number variation of the <italic>dhodh</italic> locus in 3D7 A10 parasites selected with TCMDC-125334.</title><p>Copy number was detected by quantitative PCR and calculated using the ΔΔC<sub>T</sub> method, normalizing to the 3D7 A10 parent and the 18s rRNA target. DHODH front and DHODH rear refer to two amplicons within the <italic>dhodh</italic> gene. Seryl tRNA synthase is shown as a control. 2x DHODH is control gDNA isolated from parasites with previously confirmed copy number duplication. Error bars represent minimum and maximum values of four technical replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85023-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Treatment with 1 µM TCMDC-125334 selects for moderately resistant parasite populations with copy number variation at the <italic>dhodh</italic> locus.</title><p>Schematic of selection protocol. Genetic characterization revealed that parasite populations exhibited 2x copy number variation of the <italic>dhodh</italic> locus after the first round of treatment with TCMDC-125334, and five- to eight-fold copy number variation of the <italic>dhodh</italic> locus after the second round of treatment (see <xref ref-type="fig" rid="fig2">Figure 2</xref>). Table displays dose response of parasite populations selected with TCMDC-125334. Shown are average EC<sub>50</sub>’s with standard deviation and sample number (N) defined as number of individual bioreplicates. See also <xref ref-type="supplementary-material" rid="fig2s2sdata1">Figure 2—figure supplement 2—source data 1</xref>.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Whole-genome sequencing analysis of bulk selected populations.</title><p>Status column indicates whether the mutation is present at a clonal allele frequency or mixed allele frequency since the samples were bulk populations.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85023-fig2-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85023-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Control selection with DSM265.</title><p>(<bold>A</bold>) Table describing selection procedure. Three 25 mL flasks of approximately 10<sup>8</sup> parasites were treated with 30 nM of DSM265 for 9 days. In all three flasks, parasitemia was observed 7 days post drug treatment. (<bold>B</bold>) Dose-response assay of in vitro selected bulk populations. Error bars show standard deviation of three technical replicates. See also <xref ref-type="supplementary-material" rid="fig2s3sdata1">Figure 2—figure supplement 3—source data 1</xref>.</p><p><supplementary-material id="fig2s3sdata1"><label>Figure 2—figure supplement 3—source data 1.</label><caption><title>Whole-genome sequencing analysis of bulk selected populations.</title><p>Status column indicates whether the mutation is present at a clonal allele frequency or mixed allele frequency since the samples were bulk populations.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85023-fig2-figsupp3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85023-fig2-figsupp3-v2.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>DHODH genotype and corresponding dose-response phenotype for representative in vitro TCMDC-125334 selected lines.</title><p><supplementary-material id="table1sdata1"><label>Table 1—source data 1.</label><caption><title>Individual bioreplicates of EC<sub>50</sub> values (nM) obtained from dose-response assays.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85023-table1-data1-v2.xlsx"/></supplementary-material><supplementary-material id="table1sdata2"><label>Table 1—source data 2.</label><caption><title>Copy number variation (CNV) analysis based on whole-genome sequencing.</title><p>Denoised log<sub>2</sub> copy ratios were calculated across the genic intervals of the full genome for all sequenced samples. Values were calculated using the GATK4.0 CNV detection pipeline.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85023-table1-data2-v2.xlsx"/></supplementary-material><supplementary-material id="table1sdata3"><label>Table 1—source data 3.</label><caption><title>Homozygous variants identified from in vitro selections by whole-genome sequencing.</title><p>Each entry represents a single clonal mutation that is present in the drug-selected clone but not in the matched parent line (i.e. arose during the drug selection process).</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85023-table1-data3-v2.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Clone ID</th><th align="left" valign="bottom">DHODH mutation(s)<xref ref-type="table-fn" rid="table1fn2">*</xref></th><th align="left" valign="bottom">DHODH CNV</th><th align="left" valign="bottom">TCMDC-125334 EC50 (nM)</th><th align="left" valign="bottom">DSM265EC50 (nM)</th><th align="left" valign="bottom">IDI-6273 EC50 (nM)</th><th align="left" valign="bottom">Genz669178 EC50 (nM)</th></tr></thead><tbody><tr><td align="char" char="." valign="bottom">3D7 A10</td><td align="left" valign="bottom">WT</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">140±42.6</td><td align="left" valign="bottom">4.5±1.6</td><td align="left" valign="bottom">502±209</td><td align="left" valign="bottom">6.9±2.2</td></tr><tr><td align="left" valign="bottom">T-F1-C1</td><td align="left" valign="bottom">WT</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">280±81.3</td><td align="left" valign="bottom">8.2±2.6</td><td align="left" valign="bottom">993±220</td><td align="left" valign="bottom">16.9±6.70</td></tr><tr><td align="left" valign="bottom">T-F1-C2</td><td align="left" valign="bottom">WT</td><td align="left" valign="bottom">3</td><td align="left" valign="bottom">426±146**</td><td align="left" valign="bottom">12.5±2.36*</td><td align="left" valign="bottom">1597±212*</td><td align="left" valign="bottom">27.0±10.0*</td></tr><tr><td align="left" valign="bottom">T-F2-C1</td><td align="left" valign="bottom">I263S</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">432±130.8**</td><td align="left" valign="bottom">2.5±0.74</td><td align="left" valign="bottom">7057±671**</td><td align="left" valign="bottom">26.7±15.5*</td></tr><tr><td align="left" valign="bottom">T-F2-C2</td><td align="left" valign="bottom">WT</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">137±25.1</td><td align="left" valign="bottom">4.3±0.94</td><td align="left" valign="bottom">572±91.5</td><td align="left" valign="bottom">7.79±3.42</td></tr><tr><td align="left" valign="bottom" colspan="3">Overall p-value (approximate)</td><td align="left" valign="bottom">0.0004</td><td align="left" valign="bottom">0.0013</td><td align="left" valign="bottom">0.0007</td><td align="left" valign="bottom">0.0013</td></tr><tr><td align="left" valign="bottom" colspan="3">Kruskall-Wallis statistic</td><td align="left" valign="bottom">28.52</td><td align="left" valign="bottom">25.54</td><td align="left" valign="bottom">27.05</td><td align="left" valign="bottom">25.50</td></tr></tbody></table><table-wrap-foot><fn><p>The parasite lines are each designated with a unique identifier; for example, T-F1-C1 was selected with TCDC-125334 (T) came from flask 1 (F1), and is designated as ‘C1’ for ‘Clone 1’. Data is shown as mean EC<sub>50</sub> ± standard deviation. Statistical significance was determined by a Kruskal-Wallis test, with post hoc multiple comparisons (Dunn’s) of each clone to 3D7 A10. *p<italic>≤</italic>0.05; **p<italic>≤</italic>0.01. Overall statistics are reported for each comparison group. Each dose-response assay was performed with triplicate technical replicates, and average EC<sub>50</sub>’s were obtained from 3 to 4 independent biological replicates.</p></fn><fn id="table1fn2"><label>*</label><p>Variants identified by whole-genome sequencing.</p></fn></table-wrap-foot></table-wrap><p>In a second independent selection experiment, we treated three additional parasite populations with 1 µM TCMDC-125334. Similarly, bulk populations recovered after either one or two rounds of treatment displayed moderate (~2-fold) resistance to multiple DHODH inhibitors, and exhibited CNV at the <italic>dhodh</italic> locus as detected by qPCR (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Two of the populations treated with 1 µM were subjected to a second round of treatment at 1 µM TCMDC-125334 for 13 days, then 1.5 µM TMCDC-125334 for 15 days. These populations developed a stronger resistance phenotype (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>), and correspondingly showed eight-fold increased copy number at the <italic>dhodh</italic> locus (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>), while no mutations were detected in the <italic>dhodh</italic> locus by WGS (<xref ref-type="supplementary-material" rid="fig2s2sdata1">Figure 2—figure supplement 2—source data 1</xref>).</p><p>As a control, we performed a parallel set of selections with 30 nM DSM265 (the EC<sub>99</sub>). Parasites were exposed to compound for 9 days. As previously observed, parasites resistant to DSM265 emerged rapidly after just one round of treatment, after 7 days in compound-free media (<xref ref-type="bibr" rid="bib47">Mandt et al., 2019</xref>). This was expected given that the minimum inoculation of resistance for DSM265 is 10<sup>5.5</sup> (<xref ref-type="bibr" rid="bib18">Duffey et al., 2021</xref>), and we use 10<sup>8</sup> parasites in our selection experiments. WGS of the bulk populations revealed two point mutations in <italic>dhodh</italic>—DHODH C276Y and I273M (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref>, <xref ref-type="supplementary-material" rid="fig2s3sdata1">Figure 2—figure supplement 3—source data 1</xref>).</p></sec><sec id="s2-3"><title>Sequential treatment of DSM265-resistant parasites with TCMDC125334 selects for additional mutations in <italic>dhodh</italic></title><p>Given the hypersensitivity of DHODH C276Y parasites to TCMDC-125334, we also wanted to test what would happen if we treated DHODH C276Y parasites with this compound. In our previous work, selections with two distinct DHODH inhibitors, Genz666136 and DSM74, yielded resistant parasites with a DHODH E182D mutation, which were hypersensitive to the DHODH inhibitor IDI-6273. When we treated the DHODH E182D parasite line with IDI-6273, parasites reverted to the wildtype D182 protein sequence, albeit with a different DNA codon. The D182E revertant line had a sensitivity phenotype similar to wildtype parasites (<xref ref-type="bibr" rid="bib43">Lukens et al., 2014</xref>). We hypothesized that treating DHODH C276Y parasites with TCMDC-125334 would similarly cause a reversion to wildtype, and thus offer a strategy to regain sensitivity to DSM265 (<xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Mutant parasites can overcome collateral sensitivity by acquiring additional genetic changes that confer high-level resistance to wildtype inhibitors.</title><p>(<bold>A</bold>) General schematic for sequential selection. (<bold>B</bold>) Protocol for in vitro selection. DHODH C276Y mutant parasites in three independent 25 mL culture flasks were exposed to 40 nM TCMDC-125334, then allowed to recover. The time on compound and time to recovery are indicated. After two rounds of treatment and recovery, resistant parasites are observed in all three flasks. (<bold>C</bold>) In vitro dose-response curve of selected bulk populations. Error bars show standard deviation of technical replicates. (<bold>D–E</bold>) Resistant populations were cloned by limiting dilution. Shown is the average EC<sub>50</sub> of two representative clones from each flask for TCMDC-125334 (<bold>C</bold>), and DSM265 (<bold>D</bold>), with chemical structures illustrated below. Bar graphs represent average EC<sub>50</sub> with error bars depicting standard deviation. Individual biological replicates are also shown. Each dose-response assay was performed with triplicate technical replicates, and average EC<sub>50</sub>’s were obtained from 3 to 8 independent biological replicates. The parasite lines are each designated with a unique identifier; for example, D-T-F1-C1 was selected first with DSM265 (<bold>D</bold>), then from TCMDC-125334 (<bold>T</bold>), came from flask 1 (<bold>F1</bold>), and is designated as ‘C1’ for ‘Clone 1’. DHODH genotypes for representative clones are as follows: D-T-F1-C1: DHODH C276Y+3x <italic>dhodh</italic> copy number variation (CNV); D-T-F1-C2: DHODH C276Y+4x <italic>dhodh</italic> CNV; D-T-F2-C1: DHODH C276Y+<italic>2x dhodh</italic> CNV; D-T-F2-C2: DHODH C276Y+<italic>4x dhodh</italic> CNV; D-T-F3-C1: DHODH C276Y/F227Y; D-T-F3-C2: DHODH C276Y/F227Y. Statistical significance was determined by a Kruskal-Wallis test, with post hoc multiple comparisons (Dunn’s) of each clone to 3D7 A10. In cases where the EC50 could not be determined with range of concentrations tested, the maximum concentration that achieved &gt;50% growth was used as a stand-in value. *p<italic>≤</italic>0.05; ***p<italic>≤</italic>0.001; ****p<italic>≤</italic>0.0001. See also <xref ref-type="table" rid="table2">Table 2</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref>, and <xref ref-type="supplementary-material" rid="table2sdata1">Table 2—source data 1</xref>. (<bold>F–I</bold>) The DHODH C276Y/F227Y double mutant exhibits a resistant phenotype intermediate to single mutations. The dose-response phenotypes of the DHODH C276Y/F227Y line selected in this study (clone C276Y T-F3-C3), the DHODH C276Y line previously selected with DSM265, and the DHODH F227Y line previously selected with DSM267 (<xref ref-type="bibr" rid="bib47">Mandt et al., 2019</xref>) were characterized. Shown is a representative dose-response curve for DSM265 (<bold>F</bold>) and TCMDC-125334 (<bold>G) </bold>for illustration. Error bars show standard deviation of technical replicates within a single assay.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85023-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Copy number variation of the <italic>dhodh</italic> locus in DHODH C276Y parasites selected with TCMDC-125334.</title><p>Copy number was detected by quantitative PCR and calculated using the ΔΔC<sub>T</sub> method, normalizing to the 3D7 A10 parent and the 18s rRNA target. DHODH front and DHODH rear refer to two amplicons within the <italic>dhodh</italic> gene. Seryl tRNA synthase is shown as a control. 2x DHODH is control gDNA isolated from parasites with previously confirmed copy number duplication. Error bars represent minimum and maximum values of four technical replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85023-fig3-figsupp1-v2.tif"/></fig></fig-group><p>For these experiments, we used the DHODH C276Y clone that we had previously isolated from in vitro selections with DSM265 (<xref ref-type="bibr" rid="bib47">Mandt et al., 2019</xref>). We treated three 25 mL flasks of approximately 10<sup>8</sup> DHODH C276Y parasites with 75 nM TCMDC-125334. After parasites recovered, populations were treated with a second round of 100 nM TCMDC-125334. Resistance was observed in all three bulk parasite populations recovered from this second pulse (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>). While these parasites were less sensitive to TCMDC-125334 relative to the DHODH C276Y parental line, they were still more sensitive than <italic>Pf</italic>3D7 A10 parasites with a wildtype <italic>dhodh</italic> sequence (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Clones isolated from these sequentially selected populations had a similar intermediate dose-response phenotype for TCMDC-125334 (<xref ref-type="fig" rid="fig3">Figure 3D and E</xref>, <xref ref-type="table" rid="table2">Table 2</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref>, <xref ref-type="supplementary-material" rid="table2sdata1">Table 2—source data 1</xref>). However, compared to the DHODH C276Y parent, they had greatly increased resistance to DSM265, with EC<sub>50</sub>’s&gt;200 nM (<xref ref-type="fig" rid="fig3">Figure 3E</xref>, <xref ref-type="table" rid="table2">Table 2</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref>, <xref ref-type="supplementary-material" rid="table2sdata1">Table 2—source data 1</xref>). WGS revealed that parasites retained the DHODH C276Y mutation, and gained additional mutations in <italic>dhodh</italic>, rather than reverting back to wildtype (<xref ref-type="table" rid="table2">Table 2</xref>, <xref ref-type="supplementary-material" rid="table2sdata2">Table 2—source data 2</xref>, <xref ref-type="supplementary-material" rid="table2sdata3">Table 2—source data 3</xref>). Clones isolated from flask 1 and flask 2 had increased <italic>dhodh</italic> copy number, in addition to the DHODH C276Y mutation, as confirmed by qPCR (<xref ref-type="table" rid="table2">Table 2</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="table2sdata2">Table 2—source data 2</xref>). Clones from flask 3 had gained an additional F227Y mutation (<xref ref-type="table" rid="table2">Table 2</xref>, <xref ref-type="supplementary-material" rid="table2sdata3">Table 2—source data 3</xref>). (Note that <xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="table" rid="table2">Table 2</xref> show two representative clones from each flask. See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref> for a list of all isolated parasite clones.) Overall, sequential selection of a DSM265-resistant line with TCMDC-125334 does not restore sensitivity to DSM265. While sequentially selected parasites with additional mutations in <italic>dhodh</italic> were highly resistant to DSM265, they were not cross-resistant to TCMDC-125334, suggesting that they would still be sensitive to a therapeutic dose.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>DHODH genotype and corresponding dose-response phenotype for representative in vitro selection of DHODH C276Y parent with TCMDC-125334.</title><p><supplementary-material id="table2sdata1"><label>Table 2—source data 1.</label><caption><title>Individual bioreplicates of EC50 values (nM) obtained from dose-response assays.</title><p>Data is organized in tabs by figure/table of main manuscript.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85023-table2-data1-v2.xlsx"/></supplementary-material><supplementary-material id="table2sdata2"><label>Table 2—source data 2.</label><caption><title>Copy number variation (CNV) analysis based on whole-genome sequencing.</title><p>Denoised log<sub>2</sub> copy ratios were calculated across the genic intervals of the full genome for all sequenced samples. Values were calculated using the GATK4.0 CNV detection pipeline.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85023-table2-data2-v2.xlsx"/></supplementary-material><supplementary-material id="table2sdata3"><label>Table 2—source data 3.</label><caption><title>Homozygous variants identified from in vitro selections by whole-genome sequencing.</title><p>Each entry represents a single clonal mutation that is present in the drug-selected clone but not in the matched parent line (i.e. arose during the drug selection process).</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85023-table2-data3-v2.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"><break/><break/>Clone ID</th><th align="left" valign="bottom">DHODH mutation(s)<xref ref-type="table-fn" rid="table2fn2">*</xref></th><th align="left" valign="bottom">DHODH CNV</th><th align="left" valign="bottom">TCMDC-125334 EC50 (nM)</th><th align="left" valign="bottom">DSM265EC50 (nM)</th><th align="left" valign="bottom">IDI-6273 EC50 (nM)</th><th align="left" valign="bottom">Genz669178 EC50 (nM)</th></tr></thead><tbody><tr><td align="char" char="." valign="bottom">3D7 A10</td><td align="left" valign="bottom">WT</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">140±42.6</td><td align="left" valign="bottom">4.5±1.6</td><td align="left" valign="bottom">502±209</td><td align="left" valign="bottom">6.9±2.2</td></tr><tr><td align="left" valign="bottom">C276Y Parent</td><td align="left" valign="bottom">C276Y</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">12.40±3.089****</td><td align="left" valign="bottom">63.9±19.84</td><td align="left" valign="bottom">41.7±12.7****</td><td align="left" valign="bottom">22.0±6.68</td></tr><tr><td align="left" valign="bottom">D-T-F1-C1</td><td align="left" valign="bottom">C276Y</td><td align="left" valign="bottom">3–4</td><td align="left" valign="bottom">50.3±10.4***</td><td align="left" valign="bottom">439.3±115.96*</td><td align="left" valign="bottom">185±36.1</td><td align="left" valign="bottom">&gt;106</td></tr><tr><td align="left" valign="bottom">D-T-F1-C2</td><td align="left" valign="bottom">C276Y</td><td align="left" valign="bottom">4</td><td align="left" valign="bottom">73.0±14.7</td><td align="left" valign="bottom">611±159*</td><td align="left" valign="bottom">345±64.1</td><td align="left" valign="bottom">&gt;106</td></tr><tr><td align="left" valign="bottom">D-T-F2-C1</td><td align="left" valign="bottom">C276Y</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">31.1±6.89****</td><td align="left" valign="bottom">196±56.6</td><td align="left" valign="bottom">138±44.0*</td><td align="left" valign="bottom">117±30.0</td></tr><tr><td align="left" valign="bottom">D-T-F2-C2</td><td align="left" valign="bottom">C276Y</td><td align="left" valign="bottom">4</td><td align="left" valign="bottom">77.2±25.1</td><td align="left" valign="bottom">801±270</td><td align="left" valign="bottom">326±155</td><td align="left" valign="bottom">ND</td></tr><tr><td align="left" valign="bottom">D-T-F3-C1</td><td align="left" valign="bottom">C276Y/F227Y</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">65.6±22.9*</td><td align="left" valign="bottom">9042±2985****</td><td align="left" valign="bottom">163±36.3**</td><td align="left" valign="bottom">69.7±14.5</td></tr><tr><td align="left" valign="bottom">D-T-F3-C2</td><td align="left" valign="bottom">C276Y/F227Y</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">76.3±27.7</td><td align="left" valign="bottom">9960±3923****</td><td align="left" valign="bottom">183±84.3</td><td align="left" valign="bottom">97±54.5</td></tr><tr><td align="left" valign="bottom" colspan="3">Overall p-value (approximate)</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom" colspan="3">Kruskall-Wallis statistic</td><td align="left" valign="bottom">38.12</td><td align="left" valign="bottom">47.36</td><td align="left" valign="bottom">45.55</td><td align="left" valign="bottom">54.32</td></tr></tbody></table><table-wrap-foot><fn><p>The parasite lines are each designated with a unique identifier; for example, D-T-F1-C1 was selected first with DSM265 (D), then from TCMDC-125334 (T), came from flask 1 (F1), and is designated as ‘C1’ for ‘Clone 1’. Data is shown as mean EC<sub>50</sub> ± standard deviation. Statistical significance was determined by a Kruskal-Wallis test, with post hoc multiple comparisons (Dunn’s) of each clone to 3D7 A10. *p≤0.05; **p≤0.01; ***p≤0.001; ****p≤0.0001. Overall statistics are reported for each comparison group. Each dose-response assay was performed with triplicate technical replicates, and average EC<sub>50</sub>’s were obtained from 3 to 8 independent biological replicates. WT = wildtype. ND indicates that the EC<sub>50</sub> could not be determined; parasites were resistant to the range of doses tested as indicated by lack of complete kill at the highest dose of 500 nM. A representative set of clones were tested at higher concentrations.</p></fn><fn id="table2fn2"><label>*</label><p>Variants identified by whole-genome sequencing.</p></fn></table-wrap-foot></table-wrap><p>We wanted to further characterize how the DHODH C276Y and DHODH F227Y mutations were interacting to contribute to the observed dose-response phenotypes. Compared to wildtype, the DHODH C276Y mutation alone is ~10-fold resistant to DMS265, and ~10-fold sensitive to TCMDC-125334 (<xref ref-type="table" rid="table3">Table 3</xref>). In contrast, the DHODH C276Y/F227Y double mutant is ~1000-fold resistant to DSM265. However, the double mutant line is still ~2-fold sensitive to TCMDC-125334 relative to wildtype. We had previously selected the DHODH F227Y single mutation with the triazolopyrimidine-based inhibitor DSM267, but we had not yet assessed this mutant line’s sensitivity to TCMDC-125334. We characterized the dose-response phenotype of the DHODH F227Y mutant line and found that it exhibited three-fold resistance to TCMDC-125334 (<xref ref-type="table" rid="table3">Table 3</xref>, <xref ref-type="supplementary-material" rid="table3sdata1">Table 3—source data 1</xref>). Comparing the dose-response phenotype of the single mutant lines DHODH C276Y and DHODH F227Y to the phenotype of the DHODH C276Y/F227Y double mutant, we find that the phenotype of the two mutations in combination is consistent with additivity, ruling out a negative epistatic interaction (<xref ref-type="fig" rid="fig3">Figure 3F–I</xref>, <xref ref-type="table" rid="table3">Table 3</xref>).</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Resistance phenotype of C276Y and F227Y single mutants and C276Y/F227Y double mutant compared to expected phenotype under additive epistasis.</title><p><supplementary-material id="table3sdata1"><label>Table 3—source data 1.</label><caption><title>Individual bioreplicates of EC50 values (nM) obtained from dose-response assays.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85023-table3-data1-v2.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">DHODH mutations</th><th align="left" valign="bottom">TCMDC-125334 EC50 (fold change)</th><th align="left" valign="bottom">DSM265 EC50 (fold change)</th><th align="left" valign="bottom">IDI-6273 EC50 (fold change)</th><th align="left" valign="bottom">Genz669178EC50 (fold change)</th></tr></thead><tbody><tr><td align="char" char="." valign="bottom"><bold>3D7 A10</bold></td><td align="left" valign="bottom">140±42.6</td><td align="left" valign="bottom">4.5±1.6</td><td align="left" valign="bottom">502±209</td><td align="left" valign="bottom">6.9±2.2</td></tr><tr><td align="left" valign="bottom"><bold>C276Y</bold></td><td align="left" valign="bottom">12.40±3.09 (0.089)</td><td align="left" valign="bottom">63.9±19.8 (14.2)</td><td align="left" valign="bottom">41.7±12.7 (0.083)</td><td align="left" valign="bottom">22.0±6.68 (3.2)</td></tr><tr><td align="left" valign="bottom"><bold>F227Y</bold></td><td align="left" valign="bottom">408±17.6 (2.9)</td><td align="left" valign="bottom">998±50.0 (221)</td><td align="left" valign="bottom">2210±289 (4.4)</td><td align="left" valign="bottom">18.8±3.39 (2.7)</td></tr><tr><td align="left" valign="bottom"><bold>C276Y/F227Y (D-T-F3-C1</bold>)</td><td align="left" valign="bottom">65.6±22.9 (0.46)</td><td align="left" valign="bottom">9042±2985 (2009)</td><td align="left" valign="bottom">163±36.3 (0.32)</td><td align="left" valign="bottom">69.7±14.5 (10.1)</td></tr><tr><td align="left" valign="bottom"><bold>Expected fold change for C276Y/F227Y (additive assumption</bold>)</td><td align="left" valign="bottom">0.26</td><td align="left" valign="bottom">3138</td><td align="left" valign="bottom">0.37</td><td align="left" valign="bottom">8.64</td></tr></tbody></table><table-wrap-foot><fn><p>EC<sub>50</sub> (nM) of each line is reported, with fold change relative to 3D7 A10 in parentheses. The expected fold change of the C276Y double mutant based on an assumption of additive epistasis is reported for comparison.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-4"><title>Treatment with TCMDC-125334 + DSM265 combination delays but does not prevent the emergence of resistance</title><p>Based on the collateral sensitivity observed between DSM265 and TCMDC-125334, we hypothesized that treatment with a combination of DSM265 and TCMDC-125334 would suppress the emergence of resistant parasites (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). We treated three independent populations of 10<sup>8</sup> <italic>Pf</italic>3D7 A10 parasites with both compounds simultaneously, using the EC<sub>99</sub> of each. The selected parasite populations were not resistant after one or two rounds of treatment. However, after three pulses of compound treatment totaling 63–73 days, we obtained two populations cross-resistant to both compounds (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>). Three of the four clonal lines isolated from flask 1 were moderately (~2-fold) resistant to both DSM265 and TCMDC-125334, as well as Genz669178 and IDI-6273 (<xref ref-type="fig" rid="fig4">Figure 4D–G</xref>, <xref ref-type="table" rid="table4">Table 4</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref>, <xref ref-type="supplementary-material" rid="table4sdata1">Table 4—source data 1</xref>). Copy number duplication of the <italic>dhodh</italic> locus was detected in these resistant clones by qPCR and WGS (<xref ref-type="table" rid="table4">Table 4</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="table4sdata2">Table 4—source data 2</xref>). All six clones isolated from flask 2 were four- to sixfold resistant to TCMDC-125334 and 16- to 20-fold resistant to DSM265. These clones were also ~2-fold resistant to IDI-6273, but were still sensitive to Genz669178 (<xref ref-type="fig" rid="fig4">Figure 4D–G</xref>, <xref ref-type="table" rid="table4">Table 4</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref>, <xref ref-type="supplementary-material" rid="table4sdata1">Table 4—source data 1</xref>). Sequencing revealed that these six clones had the same point mutation resulting in a DHODH V532A amino acid change (<xref ref-type="supplementary-material" rid="table4sdata3">Table 4—source data 3</xref>, <xref ref-type="supplementary-material" rid="table4sdata4">Table 4—source data 4</xref>). (Note that <xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="table" rid="table4">Table 4</xref> show two representative clones from each flask. See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref> for a list of all isolated parasite clones.) Thus, although resistance took longer to emerge with combination treatment compared to treatment with DSM265 or TCMC-125334 alone (63–73 days with combination treatment vs. 43 days with TCMDC-125334 alone and 16 days with DSM265 alone), this strategy was ultimately insufficient to prevent the emergence of parasites resistant to both compounds. This result would argue against using these compounds in combination.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Resistance to the DSM265 + TCMDC-125334 combination arose after three rounds of treatment, with cross-resistance to both compounds conferred by the novel DHODH V532A mutation.</title><p>(<bold>A</bold>) General schematic for simultaneous selection. (<bold>B</bold>) Protocol for in vitro selection with TCMDC-125334 and DSM265. Parasite populations in three independent 25 mL culture flasks were exposed to combination treatment, then allowed to recover. The time on compound and time to recovery are indicated. After three rounds of treatment and recovery, resistant parasites are observed in flasks 1 and 2. (<bold>C</bold>) In vitro dose-response curve of bulk populations from flasks 1 and 2. Error bars show standard deviation of technical replicates. (<bold>D–G</bold>) Resistant populations were cloned by limiting dilutions. Shown is the average EC<sub>50</sub> of two representative clones from each flask for TCMDC-125334 (<bold>D</bold>), DSM265 (E), Genz669178 (<bold>F</bold>), and IDI6273 (<bold>G</bold>). Bar graphs represent average EC<sub>50</sub> with error bars depicting standard deviation. Individual biological replicates are also shown. Each dose-response assay was performed with triplicate technical replicates, and average EC<sub>50</sub>’s were obtained from 3 independent biological replicates. The parasite lines are each designated with a unique identifier; for example, DT-F1-C1 was selected with DSM255 and TCDC-125334 (DT) came from flask 1 (<bold>F1</bold>), and is designated as ‘C1’ for ‘Clone 1’. Statistical significance was determined by a Kruskal-Wallis test, with post hoc multiple comparisons (Dunn’s) of each clone to 3D7 A10. *p≤0.05; **p≤0.01. See also <xref ref-type="table" rid="table3">Table 3</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref>, and <xref ref-type="supplementary-material" rid="table3sdata1">Table 3—source data 1</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85023-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Copy number variation of the <italic>dhodh</italic> locus in 3D7 A10 parasites selected with DSM265 + TCMDC-125334 simultaneously.</title><p>Copy number was detected by quantitative PCR and calculated using the ΔΔC<sub>T</sub> method, normalizing to the 3D7 A10 parent and the 18s rRNA target. DHODH front and DHODH rear refer to two amplicons within the <italic>dhodh</italic> gene. Seryl tRNA synthase is shown as a control. 2x DHODH is control gDNA isolated from parasites with confirmed copy number duplication. Error bars represent minimum and maximum values of four technical replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85023-fig4-figsupp1-v2.tif"/></fig></fig-group><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>DHODH genotype and corresponding dose-response phenotype for representative in vitro TCMDC-125334 + DSM265 selected lines.</title><p><supplementary-material id="table4sdata1"><label>Table 4—source data 1.</label><caption><title>Individual bioreplicates of EC50 values (nM) obtained from dose-response assays.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85023-table4-data1-v2.xlsx"/></supplementary-material><supplementary-material id="table4sdata2"><label>Table 4—source data 2.</label><caption><title>Copy number variation (CNV) analysis based on whole-genome sequencing.</title><p>Denoised log<sub>2</sub> copy ratios were calculated across the genic intervals of the full genome for all sequenced samples. Values were calculated using the GATK4.0 CNV detection pipeline.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85023-table4-data2-v2.xlsx"/></supplementary-material><supplementary-material id="table4sdata3"><label>Table 4—source data 3.</label><caption><title>Homozygous variants identified from in vitro selections by whole-genome sequencing.</title><p>Each entry represents a single clonal mutation that is present in the drug-selected clone but not in the matched parent line (i.e. arose during the drug selection process). Note we conducted whole-genome sequencing for two representative clones from each flask. The others were characterized via Sanger sequencing of the dhodh locus (see Source Data 4).</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85023-table4-data3-v2.xlsx"/></supplementary-material><supplementary-material id="table4sdata4"><label>Table 4—source data 4.</label><caption><title>Sanger sequencing of in vitro selected clones selected with DSM265 + TCMDC-125334.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85023-table4-data4-v2.zip"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Clone ID</th><th align="left" valign="bottom">DHODH mutation(s)</th><th align="left" valign="bottom">DHODH CNV</th><th align="left" valign="bottom">TCMDC-125334 EC50 (nM)</th><th align="left" valign="bottom">DSM265EC50 (nM)</th><th align="left" valign="bottom">IDI-6273 EC50 (nM)</th><th align="left" valign="bottom">Genz669178 EC50 (nM)</th></tr></thead><tbody><tr><td align="char" char="." valign="bottom">3D7 A10</td><td align="left" valign="bottom">WT</td><td align="char" char="." valign="bottom">1</td><td align="char" char="plusmn" valign="bottom">140±42.6</td><td align="left" valign="bottom">4.5±1.6</td><td align="left" valign="bottom">502±209</td><td align="left" valign="bottom">6.9±2.2</td></tr><tr><td align="left" valign="bottom">DT-F1-C1</td><td align="left" valign="bottom">WT<xref ref-type="table-fn" rid="table4fn2">*</xref></td><td align="char" char="." valign="bottom">2</td><td align="char" char="plusmn" valign="bottom">260±79.5</td><td align="left" valign="bottom">8.6±1.6</td><td align="left" valign="bottom">1190±276</td><td align="left" valign="bottom">15.9±3.61*</td></tr><tr><td align="left" valign="bottom">DT-F1-C2</td><td align="left" valign="bottom">WT<xref ref-type="table-fn" rid="table4fn3"><sup>†</sup></xref></td><td align="char" char="." valign="bottom">1</td><td align="char" char="plusmn" valign="bottom">153±21.0</td><td align="left" valign="bottom">6.1±0.88</td><td align="left" valign="bottom">628±117</td><td align="left" valign="bottom">7.74±1.23</td></tr><tr><td align="left" valign="bottom">DT-F2-C1</td><td align="left" valign="bottom">V532A<xref ref-type="table-fn" rid="table4fn2">*</xref></td><td align="char" char="." valign="bottom">1</td><td align="char" char="plusmn" valign="bottom">661±145**</td><td align="left" valign="bottom">79.2±19.0*</td><td align="left" valign="bottom">1320±368*</td><td align="left" valign="bottom">11.4±3.08</td></tr><tr><td align="left" valign="bottom">DT-F2-C2</td><td align="left" valign="bottom">V532A<xref ref-type="table-fn" rid="table4fn2">*</xref></td><td align="char" char="." valign="bottom">1</td><td align="char" char="plusmn" valign="bottom">536±54.4</td><td align="left" valign="bottom">82.4±23.1*</td><td align="left" valign="bottom">881±185</td><td align="left" valign="bottom">8.69±2.35</td></tr><tr><td align="left" valign="bottom" colspan="3">Overall p-value (approximate)</td><td align="char" char="." valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">0.0019</td><td align="left" valign="bottom">0.0091</td></tr><tr><td align="left" valign="bottom" colspan="3">Kruskall-Wallis statistic</td><td align="char" char="." valign="bottom">35.72</td><td align="left" valign="bottom">35.80</td><td align="left" valign="bottom">27.85</td><td align="left" valign="bottom">23.50</td></tr></tbody></table><table-wrap-foot><fn><p>The parasite lines are each designated with a unique identifier; for example, DT-F1-C1 was selected with DSM255 and TCDC-125334 (DT) came from flask 1 (F1), and is designated as ‘C1’ for ‘Clone 1’. Data is shown as mean EC<sub>50</sub> ± standard deviation. Statistical significance was determined by a Kruskal-Wallis test, with post hoc multiple comparisons (Dunn’s) of each clone to 3D7 A10. *p≤0.05; **p≤0.01. Overall statistics are reported for each comparison group. Each dose-response assay was performed with triplicate technical replicates, and average EC<sub>50</sub>’s were obtained from 3 independent biological replicates. WT = wildtype.</p></fn><fn id="table4fn2"><label>*</label><p>DHODH genotype determined by whole-genome sequencing.</p></fn><fn id="table4fn3"><label>†</label><p>DHODH genotype determined by Sanger sequencing.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-5"><title>In silico docking of TCMDC-125334 to <italic>Pf</italic>DHODH suggests molecular mechanisms of resistance</title><p>To better understand the binding mode of TCMDC-125334 and develop inferences on the molecular mechanisms by which mutations characterized in this study may confer resistance or hypersensitivity to the compound, we performed in silico molecular docking using Flare, v.4.0.3.40719 (Cresset-Group). The co-crystal structures of DHODH, flavin mononucleotide (FMN), orotate, and a variety of inhibitors have previously been reported, but there is no reported structure with TCMDC-125334 (<xref ref-type="bibr" rid="bib58">Phillips et al., 2015</xref>; <xref ref-type="bibr" rid="bib71">White et al., 2019</xref>; <xref ref-type="bibr" rid="bib63">Ross et al., 2014</xref>; <xref ref-type="bibr" rid="bib7">Booker et al., 2010</xref>). The best pose predicted by our simulations shows that TCMDC-125334 docks within same hydrophobic binding pocket as DSM265 and other DHODH inhibitors (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>). As with all published crystal structures of DHODH inhibitors, our simulations suggest that TCMDC-125334 binds allosterically with regard to both orotate/dihydroorotate and FMN.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Molecular docking of TCMDC-125334 with <italic>Pf</italic>DHODH.</title><p>(<bold>A</bold>) TCMDC-125334 docks within the inhibitor binding pocket of DHODH. Shown is overlay of TCMDC-125334 docked in combined structure, and DSM265 from the 4XR0 structure. (<bold>B</bold>) Mutations conferring cross-resistance or collateral sensitivity are in close proximity to TCMDC-125334. Key residues discussed in the study are highlighted. Residues conferring cross-resistance are shown in red, while residues conferring collateral sensitivity are in blue. The F227 residue is colored purple, as the F227L and F227I substitutions confer collateral sensitivity while the F227Y substitution confers resistance. Structure labeled ORO is the orotic acid product. FMN is the flavin mononucleotide cofactor.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85023-fig5-v2.tif"/></fig><p>Our docking results suggest that the DHODH<sup>V532A</sup> mutation would disrupt hydrophobic interactions with the furan and 1,3,4-oxadiazole rings, consistent with the observed 5.3-fold resistance seen with the DHODH<sup>V532A</sup> mutants. There are no published crystal structures for the DHODH<sup>C276Y</sup> so we used Flare’s mutate function to produce a model of DHODH<sup>C276Y</sup>, optimized the results in the absence of other molecules and then in the presence of TCMDC-125334, orotate, and FMN with Flare’s protein minimize function, and rescored the result. Our simulation predicted that the DHODH<sup>C276Y</sup> mutant would have higher affinity for TCMDC-125334 than wildtype.</p></sec><sec id="s2-6"><title>Cross-resistant parasites are relatively fit in in vitro growth assays</title><p>Given that the DHODH V532A mutation confers cross-resistance to DSM265 and TCMDC-125334, we wanted to assess the relative fitness of <italic>P. falciparum</italic> parasites carrying this mutation. Previously we have shown that some <italic>dhodh</italic> mutations, such as DHODH E182D, can negatively impact enzyme function and in vitro growth, while other mutations, such as DHODH C276Y, do not appear to confer a fitness cost (<xref ref-type="bibr" rid="bib47">Mandt et al., 2019</xref>; <xref ref-type="bibr" rid="bib63">Ross et al., 2014</xref>). Because resistance to simultaneous selection with DSM265 and TCMDC-125334 took longer to emerge, we hypothesized that DHODH V532A mutants might have a growth defect relative to wildtype parasites. To test this hypothesis, we performed in vitro competitive growth assays. Synchronized DHODH V532A and wildtype 3D7 A10 lines were mixed in a 1:1 ratio. The mixed culture was grown in three independent flasks over a 4-week period in compound-free media, and genomic DNA was collected every 7–9 days. The ratio of mutant and wildtype parasites was determined by calculating the percentage of reads detecting the V532A allele in WGS. This analysis showed that the DHODH V532A variant remained at ~50% frequency over time (<xref ref-type="fig" rid="fig6">Figure 6</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). As a confirmation of this result, we also assessed the resistance phenotype of mixed cultures. On day 0, the mixed culture exhibited an intermediate dose-response phenotype, as illustrated by a biphasic dose-response curve. This intermediate phenotype was maintained at day 28 (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Overall, both the genotypic and phenotypic data indicate that the DHODH V532A mutant is as fit as wildtype parasites.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>The DHODH V532A mutation does not confer a fitness cost in in vitro competitive growth assays.</title><p>(<bold>A</bold>) Schematic of competitive growth experiments. Synchronized 3D7 parent and DHODH V532A mutant parasites at 1% ring-stage parasitemia were mixed at equal ratios. The mixed culture was then split into three independent flasks, and followed over time. Mixed cultures were grown for 4 weeks, and genomic DNA was collected every 7–9 days. (<bold>B</bold>) The percent mutant allele was calculated at each timepoint based on whole-genome sequencing reads (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1f</xref>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85023-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Co-cultured parasites in competition assay retain an intermediate phenotype.</title><p>3D7 parent and DHODH V532A mutant parasites at 1% ring-stage parasitemia were mixed at equal ratio and separated into three independent flasks. Mixed cultures were grown for 4 weeks. Dose-response assays were conducted at day 0, day 17, and day 28. Upper and middle panels show the dose response for DSM265 and TCMDC-125334, respectively, which differ between the 3D7 A10 wildtype and DHODH V532A strains. The bottom panel shows the dose response for dihydroartemisinin (DHA) as a control. Error bars show standard deviation of three technical replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85023-fig6-figsupp1-v2.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The main conclusion of our study is that combining two DHODH inhibitors, DSM265 and TCDC-125334, based on their collateral sensitivity profiles fails to prevent the emergence of resistance in <italic>P. falciparum</italic> in vitro. Although all previously identified mutations that we tested exhibited sensitivity to TCMDC-125334, we identified the point mutation DHODH I263S in selection with TCMDC-125334 alone, which was resistant to TCMDC-125334 but not DSM265. We found that sequentially treating a collaterally sensitive mutant line with TCMDC-125334 selected for parasites with additional genetic changes in <italic>dhodh</italic>, including the DHODH F227Y mutation, which alone also confers resistance to TCMDC-125334. While the DHODH C276Y/F227Y double mutant is less sensitive than the DHODH C276Y parent, it is still more sensitive to TCMDC-125334 compared to wildtype parasites. Finally, we found that treatment with DSM265 and TCMDC-125334 in combination selected for cross-resistant parasites with a DHODH V532A mutation. We also demonstrated that the DHODH V532A mutation does not exhibit a fitness cost in in vitro competitive growth assays.</p><p>While we identified three point mutations in this study that confer resistance to TCMDC-125334, the majority of <italic>dhodh</italic> mutations tested thus far are sensitive to this molecule. CNV was a common mechanism of resistance to TCMDC-125334 across multiple independent selections. Three of four populations of wildtype 3D7 A10 selected with TCMDC-125334 exhibited increased copy number of <italic>dhodh</italic>. When we selected the collaterally sensitive DHODH C276Y line with TCMDC-125334, clones isolated from two of three independent populations exhibited two- to fourfold CNV of <italic>dhodh</italic>. In contrast to this, the majority of in vitro selections with DSM265 and DSM267 selected for point mutations in the <italic>dhodh</italic> locus, with CNVs occurring only seldomly (<xref ref-type="bibr" rid="bib47">Mandt et al., 2019</xref>). While CNVs confers cross-resistance across various DHODH inhibitor compound classes, this mechanism confers only moderately reduced susceptibility. CNVs are also less evolutionarily stable compared to point mutations. Others have shown that additional copies of <italic>dhodh</italic> are lost in in vitro culture over time (<xref ref-type="bibr" rid="bib24">Guler et al., 2013</xref>).</p><p>Our finding that sequentially treating the DHODH C276Y line with a second inhibitor led to the acquisition of additional genetic changes, rather than reversion back to wildtype, has important implications for treatment strategies to manage resistance. This result is in contrast with our previous work, in which selecting DHODH E182D parasites with the mutant-type inhibitor IDI-6273 caused parasites to revert back to the wildtype amino acid sequence. Interestingly, we also observed that the DHODH E182D parasite had a competitive fitness defect (<xref ref-type="bibr" rid="bib43">Lukens et al., 2014</xref>; <xref ref-type="bibr" rid="bib63">Ross et al., 2014</xref>), while we previously showed that the DHODH C276Y is as fit as wildtype in in vitro competitive growth assays (<xref ref-type="bibr" rid="bib47">Mandt et al., 2019</xref>). Previous research on collateral sensitivity in <italic>Pseudomonas aeruginosa</italic> from Barbosa et al. suggests that differing evolutionary outcomes (reversion vs. secondary mutation) may be due to differences in the fitness cost of the initial resistance mutations (<xref ref-type="bibr" rid="bib3">Barbosa et al., 2019</xref>). Similarly, we saw that the competitively fit DHODH C276Y line favored alternative pathways to cross-resistance rather than reversion to wildtype. Our work has implications for strategies such as drug cycling or the simultaneous use of multiple first-line treatments that aim to delay the emergence of resistance (<xref ref-type="bibr" rid="bib6">Boni et al., 2008</xref>; <xref ref-type="bibr" rid="bib29">Huijben and Paaijmans, 2018</xref>). Such strategies assume that resistance mutations will disappear in the absence of pressure from the original selecting agent. However, our results suggest that treatment with a second compound can also result in the acquisition of additional genetic changes and subsequent multidrug resistance.</p><p>Comparing the phenotype of the DHDOH C276Y/F227Y double mutant with DHODH C276Y and DHODH F227Y parasite lines, we also note that the two mutations in combination exhibit additive epistasis. This resulted in markedly high-level resistance to DSM265 (&gt;1000-fold relative to wildtype). Multiple studies indicate that epistasis is an important factor in determining the evolution of resistance and cross-resistance/collateral sensitivity (<xref ref-type="bibr" rid="bib62">Rosenkilde et al., 2019</xref>; <xref ref-type="bibr" rid="bib3">Barbosa et al., 2019</xref>; <xref ref-type="bibr" rid="bib1">Apjok et al., 2019</xref>; <xref ref-type="bibr" rid="bib42">Lozovsky et al., 2009</xref>; <xref ref-type="bibr" rid="bib14">Dellus-Gur et al., 2015</xref>). Negative epistasis between resistance mutations within the same enzyme constrains the number of pathways to higher-level resistance (<xref ref-type="bibr" rid="bib42">Lozovsky et al., 2009</xref>; <xref ref-type="bibr" rid="bib14">Dellus-Gur et al., 2015</xref>). In the context of collateral sensitivity, the study from <xref ref-type="bibr" rid="bib3">Barbosa et al., 2019</xref> also indicates that re-sensitization to wildtype is favored when there is negative epistasis between resistance mechanisms. In contrast, our result highlights how, under additive epistasis, the emergence of an initial resistance mutation can open up pathways to higher-level resistance. The major take-away of this study is that combination treatment with DSM265 and TCMDC-125334 failed to suppress resistance, and we hypothesize that this is due to the great diversity of evolutionarily competitive <italic>dhodh</italic> mutations that confer resistance to various inhibitors. Other reports in bacteria have also found that observed patterns of collateral sensitivity are often thwarted due to the existence of diverse trajectories to resistance. When selections are repeated enough times (<xref ref-type="bibr" rid="bib52">Nichol et al., 2019</xref>), or are performed with a large enough starting populations (<xref ref-type="bibr" rid="bib32">Jiao et al., 2016</xref>), cross-resistant variants eventually emerge, even if they are relatively rare. Similarly, we find that although most of the mutations we originally identified were collaterally sensitive to TCMDC-125334, repeated treatment with DSM265 and TCMDC-125334 in combination ultimately yielded the cross-resistant variant DHODH V532A. There were also additional mutations outside the <italic>dhodh</italic> locus observed in the WGS analysis that were not repeated across multiple independent selections and so are less likely to contribute to the resistance phenotype (<xref ref-type="supplementary-material" rid="table1sdata3">Table 1—source data 3</xref>; <xref ref-type="supplementary-material" rid="table2sdata3">Table 2—source data 3</xref>; <xref ref-type="supplementary-material" rid="table4sdata3">Table 4—source data 3</xref>). Additionally, we have previously conducted allelic replacements with mutations in DHODH which have phenocopied the selected lines, suggesting that these mutations are the primary driver of the observed resistance phenotypes (<xref ref-type="bibr" rid="bib47">Mandt et al., 2019</xref>).</p><p>We cannot quantify the frequency of resistance emergence based on our results, which would be necessary to fully understand the risk of resistance to DSM265 + TCMDC-125334 in combination compared to treating with either compound alone. However, we did find that the DHODH V532A mutation conferring cross-resistance to both compounds emerged from a population of 10<sup>8</sup> parasites after three treatment cycles. In contrast, there can be 10<sup>10</sup>–10<sup>13</sup> parasites in an infected human host, suggesting that this would be a sufficient population size for cross-resistance to emerge (<xref ref-type="bibr" rid="bib21">Goldberg et al., 2012</xref>; <xref ref-type="bibr" rid="bib8">Bopp et al., 2013</xref>).</p><p>This study also highlights the flexibility of the DHODH enzyme. Prior to this work, we had identified 13 individual point mutations and 2 sets of double mutations that conferred resistance to DHODH. In this study, we selected two additional point mutations—DHODH I263S and DHODH V532A—as well as the DHODH C276Y/F227Y double mutant line. Interestingly, the DHODH I263S mutation is not resistant to DSM265, while the DHODH I263F mutation at the same site confers strong (~100-fold) resistance to this compound. Previous studies have crystallized the DHODH enzyme bound to various inhibitors, including DMS265 (PDB 4<italic>R</italic>X0), Genz669178 (PDB 4CQ8), and IDI-6273 (PDB 4CQA) (<xref ref-type="bibr" rid="bib58">Phillips et al., 2015</xref>; <xref ref-type="bibr" rid="bib43">Lukens et al., 2014</xref>). These compounds all bind within the same flexible pocket (see <xref ref-type="fig" rid="fig1">Figure 1A</xref>) of the enzyme. Our results demonstrate that this pocket not only accommodates the binding of a variety of chemical structures, but is also very mutationally flexible, highlighting the resistance liability of this enzyme as a drug target. Molecular simulation studies provided insight into the potential mechanism of resistance to both DSM265 and TCMDC-125334, highlighting the interactions at position V532. However, understanding the mechanism of collateral sensitivity will require further study. Molecular simulation points to differential binding affinity of TCMDC-125334 to the wildtype and C276Y mutant proteins, consistent with the increased sensitivity of the mutant observed in our study (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</p><p>The in vitro studies described here also provide a framework for future in vivo work. We previously demonstrated that with DSM265 alone, the in vitro data is a good predictor of the in vivo evolution of resistance (<xref ref-type="bibr" rid="bib47">Mandt et al., 2019</xref>). It will be important to test potential combination strategies in vivo, as pharmacokinetics and pharmacodynamics may impact how multiple drugs interact with each other, with implications for the emergence of resistance. However, our continued identification of novel point mutations in the <italic>dhodh</italic> locus suggests that we still have not saturated the <italic>dhodh</italic> resistome. Additional mutational pathways to resistance could potentially be identified through further resistance selections or high-throughput methods such as deep mutational scanning to assess variants. The mutational flexibility of the inhibitor binding site in DHODH increases the likelihood of resistance to any compound or compound combination that targets this site. CNV also appears to be a general mechanism of resistance to multiple chemical classes of DHODH inhibitors. One implication of these results is that targeting this enzyme with antimalarial drugs has a high risk of resistance emergence and brings into question the usefulness of pursuing further DHODH inhibitors.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Reagents and parasite lines</title><p>Atovaquone, dihydroartemisinin, and mefloquine were purchased from Sigma-Aldrich (St. Louis, MO, USA). IDI-6273 was purchased from ChemDiv (San Diego, CA, USA). Genz669178 was graciously provided by Genzyme, a Sanofi Company (Waltham, MA, USA). DSM265 was a kind gift from Margaret Phillips of University of Texas Southwestern (Dallas, TX, USA). The <italic>Pf</italic>3D7 A10 clone used in this study was adapted to a 40 hr replication cycle in in vitro culture, and has been previously used in large-scale selection and sequencing efforts (<xref ref-type="bibr" rid="bib12">Cowell et al., 2018</xref>). The identity of the parental parasite lines used in this study (3D7 A10 and DHODH C276Y) were verified by WGS and alignment to the reference genome. The parental parasite cultures tested negative for mycoplasma using the LookOut Mycoplasma PCR Detection Kit (Sigma). The identity of clones generated over the course of the study were also validated by sequencing and <italic>Mycoplasma</italic> status tested as above. All cell lines were negative for mycoplasma. Parasites with point mutations in <italic>Pf</italic>DHODH derived from previous work were generated as described and identity verified by sequencing (<xref ref-type="bibr" rid="bib47">Mandt et al., 2019</xref>; <xref ref-type="bibr" rid="bib63">Ross et al., 2014</xref>). Compounds from GSK libraries were previously published in <xref ref-type="bibr" rid="bib64">Ross et al., 2018</xref> (Key Resources Table).</p></sec><sec id="s4-2"><title>In vitro parasite culturing</title><p>Parasites were cultured by standard methods with RPMI 1640 (Life Technologies) in 5% O<sup>+</sup> human blood obtained from Interstate Blood Bank. RPMI 1640 was supplemented with 28 mM NaHCO<sub>3</sub>, 25 mM HEPES, 50 mg/mL hypoxanthine, 2525 μg/mL gentamycin, and 0.5% Albumax II (Life Technologies). Parasite cultures were maintained in a gas mixture of 95% N<sub>2</sub>, 4% CO<sub>2</sub>, and 1.1% O<sub>2</sub> at 37°C. Parasites were regularly synchronized by 5% sorbitol treatment (<xref ref-type="bibr" rid="bib38">Lambros and Vanderberg, 1979</xref>), and all lines generated were preserved in glycerol stocks stored in liquid nitrogen.</p></sec><sec id="s4-3"><title>Resistance selections</title><p>In vitro resistance selections were performed in triplicate 25 mL flasks with 3–4% ring-stage parasitemia. Selected populations were treated with the indicated dose of compound in RPMI daily until parasites were no longer visible by thin smear microscopy. Cultures were then replenished with compound-free RPMI and monitored every 2–5 days by microscopy. Bulk recrudescent cultured were phenotyped in dose-response assays. Resistant populations were cloned by limiting dilution in 96-well plates at a density of 0.2 parasites per well in the absence of compound. For complete list of cell lines generated, see Key Resources Table.</p></sec><sec id="s4-4"><title>Dose-response assays</title><p>To assess susceptibility phenotypes of parasite lines, ring-stage parasites were grown at 1% hematocrit, 1% starting parasitemia in 40 µL volumes in 384-well black clear-bottomed plates. Parasites were cultured in the presence of test compounds plated in triplicate concentrations in 12-point serial dilutions, and parasite growth after 72 hr was measured by a SYBR Green-based fluorescence assay (<xref ref-type="bibr" rid="bib34">Johnson et al., 2007</xref>; <xref ref-type="bibr" rid="bib68">Smilkstein et al., 2004</xref>). Lysis buffer with SYBR Green I at 10× concentration was added to the plates and allowed to incubate at room temperature for at least 12 hr. Fluorescence was measured at 494 nm excitation, 530 nm emission. Data was analyzed with CCD Vault, which calculates EC<sub>50</sub> values based on a non-linear dose-response curve fit (Burlingame, CA, USA).</p></sec><sec id="s4-5"><title>Genomic DNA analysis</title><p>For genetic characterization of resistant clones, red blood cells infected with late-stage parasites were washed with 0.1% saponin to obtain isolated parasite pellets. For competitive growth assays, ring-stage infected red blood cells were directly suspended in DNA/RNA Shield (Zymo Research). Genomic DNA was then extracted using a DNAeasy Blood and Tissue Kit (QIAGEN).</p><sec id="s4-5-1"><title><bold>W</bold>hole-genome sequencing</title><p>Libraries were prepared with the standard dual index protocol of the Nextera XT kit (Cat. No FC-131-1024). WGS was performed on an Illumina NovaSeq 6000 with S4 200 chemistry and 100 bp paired end reads. The <italic>P. falciparum</italic> 3D7 genome (PlasmoDB v. 13.0) was used as a reference for read alignment. Variants were called using an established analysis pipeline as previously described, where mutations are identified that are present in selected parasites that are not in the original parent line (<xref ref-type="bibr" rid="bib12">Cowell et al., 2018</xref>). CNV was determined based on differential DNA sequence coverage as previously described (<xref ref-type="bibr" rid="bib12">Cowell et al., 2018</xref>). A table with the coverage for each run is given in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1g</xref>.</p></sec><sec id="s4-5-2"><title>PCR and Sanger sequencing</title><p>Six of the ten clones from the DSM265 + TCMDC-125334 combination selection were genetically characterized by Sanger sequencing. PCR amplification of the <italic>dhodh</italic> locus was performed using Phusion High-Fidelity PCR Master Mix (New England BioLabs) as per the protocol. The locus was amplified in three overlapping segments with primers listed in the Key Resources Table.</p></sec><sec id="s4-5-3"><title>Quantitative PCR to assess CNV</title><p>Copy number of the <italic>dhodh</italic> locus was assessed by quantitative PCR (qPCR) as previously described (<xref ref-type="bibr" rid="bib63">Ross et al., 2014</xref>), with primers listed in the Key Resources Table with power SYBR Green Master Mix (Applied Biosystems) and 0.1 ng gDNA template. qPCR was performed on a ViiA7 real-time PCR system with 384-well block (Applied Biosystems), and relative copy number was calculated using the ΔΔC<sub>T</sub> method.</p></sec></sec><sec id="s4-6"><title>In silico molecular modeling</title><p>For the modeling simulations conducted with Flare v.4.0.3.40719 (Cresset-Group), the DHODH crystal structures (PDB codes: 4<italic>R</italic>X0, 3O8A, 4CQ8, 4CQA, and 4CQ9) were imported from the PDB and ‘Protein Prep’ was performed using the default settings. Sequences were aligned and all structures superimposed to 4<italic>R</italic>X0. Three forms of TCMDC-125334 (unspecified enantiomer, R-isomer, and S-isomer) were then docked to all sequences using ensemble docking with the docking grid defined as all residues. Docking was performed using ‘Very Accurate but Slow’ settings modified to allow rotation about amide bonds. Mutant structures were prepared with Flare’s mutate function using default settings, energy minimized with Flare’s protein minimize function in the absence of other molecules and then in the presence of TCMDC-125334, orotate, and FMN, and then rescored as described above. Simulations were visualized using PyMOL v. 4.6.0 (Intel).</p></sec><sec id="s4-7"><title>Competition growth assays</title><p>Mutant and wildtype cultures were synchronized at least twice prior to the assay. Ring-stage mutant and wildtype parasites at 5% hematocrit and 1% parasitemia were combined at equal volumes. Mixed culture was split into three 10 mL replicate flasks, which were maintained for 4 weeks. Genomic DNA samples were collected and dose-response assays performed at indicated timepoints.</p></sec><sec id="s4-8"><title>Statistical analysis</title><p>The heatmap visualizing patterns of cross-resistance and collateral sensitivity was created using MultiExperimentViewer (MeV) version 4.9.0. Hierarchical clustering of both parasite lines and compounds was performed based on Euclidean distance using average linkage. Prism v8 (GraphPad) was used to make graphs and to perform statistical analysis comparing EC<sub>50</sub>’s of selected parasite clones and wildtype 3D7 A10. Significance was determined using a non-parametric ANOVA test (Kruskall-Wallis) with post hoc multiple comparisons (Dunn’s test).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>The work discussed in this article was performed by REKM elsewhere prior to becoming a federal employee. The article was written/edited by REKM in her private capacity. No official support or endorsement by the National Institute of Allergy and Infectious Diseases is intended or should be inferred</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>Sits on the advisory board of the Tres Cantos Open Lab Foundation</p></fn><fn fn-type="COI-statement" id="conf4"><p>GlaxoSmithKline employee</p></fn><fn fn-type="COI-statement" id="conf5"><p>Sits on the advisory board of Medicines for Malaria Venture</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Investigation, Visualization, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Data curation, Software, Methodology, Writing – original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Software, Investigation, Writing – original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Supervision, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Supervision, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Supplementary tables with additional experimental information for ‘Diverse evolutionary pathways pose a challenge to the use of collateral sensitivity as a strategy to suppress resistance’.</title></caption><media xlink:href="elife-85023-supp1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-85023-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The raw whole-genome sequencing data generated in this study have been submitted to the NCBI Sequence Read Archive database (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sra/">https://www.ncbi.nlm.nih.gov/sra/</ext-link>) under accession number PRJNA689594. Sanger sequencing of the PCR amplified dhodh locus have been submitted to GenBank (NCBI) under accession numbers MZ571149-MZ571158.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Mandt</surname><given-names>REK</given-names></name><name><surname>Luth</surname><given-names>MR</given-names></name><name><surname>Tye</surname><given-names>MA</given-names></name><name><surname>Mazitschek</surname><given-names>R</given-names></name><name><surname>Ottilie</surname><given-names>S</given-names></name><name><surname>Winzeler</surname><given-names>EA</given-names></name><name><surname>Lafuente-Monasterio</surname><given-names>MJ</given-names></name><name><surname>Gamo</surname><given-names>FJ</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name><name><surname>Lukens</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title><italic>Plasmodium falciparum</italic> strain 3D7 A10 clone DT-F1-C1 dihydroorotate dehydrogenase (dhodh) gene, complete cds</data-title><source>NCBI Nucleotide</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/MZ571149">MZ571149</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Mandt</surname><given-names>REK</given-names></name><name><surname>Luth</surname><given-names>MR</given-names></name><name><surname>Tye</surname><given-names>MA</given-names></name><name><surname>Mazitschek</surname><given-names>R</given-names></name><name><surname>Ottilie</surname><given-names>S</given-names></name><name><surname>Winzeler</surname><given-names>EA</given-names></name><name><surname>Lafuente-Monasterio</surname><given-names>MJ</given-names></name><name><surname>Gamo</surname><given-names>FJ</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name><name><surname>Lukens</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title><italic>Plasmodium falciparum</italic> strain 3D7 A10 clone DT-F1-C2 dihydroorotate dehydrogenase (dhodh) gene, complete cds</data-title><source>NCBI Nucleotide</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/MZ571150">MZ571150</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset3"><person-group person-group-type="author"><name><surname>Mandt</surname><given-names>REK</given-names></name><name><surname>Luth</surname><given-names>MR</given-names></name><name><surname>Tye</surname><given-names>MA</given-names></name><name><surname>Mazitschek</surname><given-names>R</given-names></name><name><surname>Ottilie</surname><given-names>S</given-names></name><name><surname>Winzeler</surname><given-names>EA</given-names></name><name><surname>Lafuente-Monasterio</surname><given-names>MJ</given-names></name><name><surname>Gamo</surname><given-names>FJ</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name><name><surname>Lukens</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title><italic>Plasmodium falciparum</italic> strain 3D7 A10 clone DT-F1-C3 dihydroorotate dehydrogenase (dhodh) gene, complete cds</data-title><source>NCBI Nucleotide</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/MZ571151">MZ571151</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset4"><person-group person-group-type="author"><name><surname>Mandt</surname><given-names>REK</given-names></name><name><surname>Luth</surname><given-names>MR</given-names></name><name><surname>Tye</surname><given-names>MA</given-names></name><name><surname>Mazitschek</surname><given-names>R</given-names></name><name><surname>Ottilie</surname><given-names>S</given-names></name><name><surname>Winzeler</surname><given-names>EA</given-names></name><name><surname>Lafuente-Monasterio</surname><given-names>MJ</given-names></name><name><surname>Gamo</surname><given-names>FJ</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name><name><surname>Lukens</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title><italic>Plasmodium falciparum</italic> strain 3D7 A10 clone DT-F1-C4 dihydroorotate dehydrogenase (dhodh) gene, complete cds</data-title><source>NCBI Nucleotide</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/MZ571152">MZ571152</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset5"><person-group person-group-type="author"><name><surname>Mandt</surname><given-names>REK</given-names></name><name><surname>Luth</surname><given-names>MR</given-names></name><name><surname>Tye</surname><given-names>MA</given-names></name><name><surname>Mazitschek</surname><given-names>R</given-names></name><name><surname>Ottilie</surname><given-names>S</given-names></name><name><surname>Winzeler</surname><given-names>EA</given-names></name><name><surname>Lafuente-Monasterio</surname><given-names>MJ</given-names></name><name><surname>Gamo</surname><given-names>FJ</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name><name><surname>Lukens</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title><italic>Plasmodium falciparum</italic> strain 3D7 A10 clone DT-F2-C1 dihydroorotate dehydrogenase (dhodh) gene, complete cds</data-title><source>NCBI Nucleotide</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/MZ571153">MZ571153</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset6"><person-group person-group-type="author"><name><surname>Mandt</surname><given-names>REK</given-names></name><name><surname>Luth</surname><given-names>MR</given-names></name><name><surname>Tye</surname><given-names>MA</given-names></name><name><surname>Mazitschek</surname><given-names>R</given-names></name><name><surname>Ottilie</surname><given-names>S</given-names></name><name><surname>Winzeler</surname><given-names>EA</given-names></name><name><surname>Lafuente-Monasterio</surname><given-names>MJ</given-names></name><name><surname>Gamo</surname><given-names>FJ</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name><name><surname>Lukens</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title><italic>Plasmodium falciparum</italic> strain 3D7 A10 clone DT-F2-C2 dihydroorotate dehydrogenase (dhodh) gene, complete cds</data-title><source>NCBI Nucleotide</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/MZ571154">MZ571154</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset7"><person-group person-group-type="author"><name><surname>Mandt</surname><given-names>REK</given-names></name><name><surname>Luth</surname><given-names>MR</given-names></name><name><surname>Tye</surname><given-names>MA</given-names></name><name><surname>Mazitschek</surname><given-names>R</given-names></name><name><surname>Ottilie</surname><given-names>S</given-names></name><name><surname>Winzeler</surname><given-names>EA</given-names></name><name><surname>Lafuente-Monasterio</surname><given-names>MJ</given-names></name><name><surname>Gamo</surname><given-names>FJ</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name><name><surname>Lukens</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title><italic>Plasmodium falciparum</italic> strain 3D7 A10 clone DT-F2-C3 dihydroorotate dehydrogenase (dhodh) gene, complete cds</data-title><source>NCBI Nucleotide</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/MZ571155">MZ571155</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset8"><person-group person-group-type="author"><name><surname>Mandt</surname><given-names>REK</given-names></name><name><surname>Luth</surname><given-names>MR</given-names></name><name><surname>Tye</surname><given-names>MA</given-names></name><name><surname>Mazitschek</surname><given-names>R</given-names></name><name><surname>Ottilie</surname><given-names>S</given-names></name><name><surname>Winzeler</surname><given-names>EA</given-names></name><name><surname>Lafuente-Monasterio</surname><given-names>MJ</given-names></name><name><surname>Gamo</surname><given-names>FJ</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name><name><surname>Lukens</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title><italic>Plasmodium falciparum</italic> strain 3D7 A10 clone DT-F2-C4 dihydroorotate dehydrogenase (dhodh) gene, complete cds</data-title><source>NCBI Nucleotide</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/MZ571156">MZ571156</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset9"><person-group person-group-type="author"><name><surname>Mandt</surname><given-names>REK</given-names></name><name><surname>Luth</surname><given-names>MR</given-names></name><name><surname>Tye</surname><given-names>MA</given-names></name><name><surname>Mazitschek</surname><given-names>R</given-names></name><name><surname>Ottilie</surname><given-names>S</given-names></name><name><surname>Winzeler</surname><given-names>EA</given-names></name><name><surname>Lafuente-Monasterio</surname><given-names>MJ</given-names></name><name><surname>Gamo</surname><given-names>FJ</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name><name><surname>Lukens</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title><italic>Plasmodium falciparum</italic> strain 3D7 A10 clone DT-F2-C5 dihydroorotate dehydrogenase (dhodh) gene, complete cds</data-title><source>NCBI Nucleotide</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/MZ571157">MZ571157</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset10"><person-group person-group-type="author"><name><surname>Mandt</surname><given-names>REK</given-names></name><name><surname>Luth</surname><given-names>MR</given-names></name><name><surname>Tye</surname><given-names>MA</given-names></name><name><surname>Mazitschek</surname><given-names>R</given-names></name><name><surname>Ottilie</surname><given-names>S</given-names></name><name><surname>Winzeler</surname><given-names>EA</given-names></name><name><surname>Lafuente-Monasterio</surname><given-names>MJ</given-names></name><name><surname>Gamo</surname><given-names>FJ</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name><name><surname>Lukens</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title><italic>Plasmodium falciparum</italic> strain 3D7 A10 clone DT-F2-C6 dihydroorotate dehydrogenase (dhodh) gene, complete cds</data-title><source>NCBI Nucleotide</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/MZ571158">MZ571158</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset11"><person-group person-group-type="author"><collab>University of California, San Diego</collab></person-group><year iso-8601-date="2021">2021</year><data-title>WGS of <italic>Plasmodium falciparum</italic> selected with DHODH inhibitors</data-title><source>NCBI BioProject</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA689594/">PRJNA689594</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank M Phillips (UT Southwestern) and J Burrows (Medicines for Malaria Venture) for generously providing compounds DSM265 and DSM267. We are also grateful to P Hinkson (Harvard TH Chan School of Public Health) for technical support. We are grateful for generous financial support by the NIH (grant no. R01 AI093716 to DFW), the Bill and Melinda Gates Foundation (Grand Challenges Exploration grant no. OPP1132451 to DFW, AKL, and FJG.), and the Harvard Malaria Initiative with support from ExxonMobil Foundation (to DFW). REKM was additionally supported by the Harvard Herchel Smith Fellowship, an NIH T32 grant, and funds from the ExxonMobil Foundation. MRL was supported in part by a Ruth L Kirschstein Institutional National Research Service Award T32 GM008666 from the National Institute of General Medical Sciences. This publication includes data generated at the UC San Diego IGM Genomics Center utilizing an Illumina NovaSeq 6000 that was purchased with funding from a National Institutes of Health SIG grant (#S10 OD026929). R.E.K.M. present address: National Institute of Allergy and Infectious Diseases, National Institutes of Health. Bethesda, Maryland. The work discussed in this article was performed by R.E.K.M. elsewhere prior to becoming a federal employee. The article was written/edited by R.E.K.M. in her private capacity. No official support or endorsement by the is intended or should be inferred.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apjok</surname><given-names>G</given-names></name><name><surname>Boross</surname><given-names>G</given-names></name><name><surname>Nyerges</surname><given-names>Á</given-names></name><name><surname>Fekete</surname><given-names>G</given-names></name><name><surname>Lázár</surname><given-names>V</given-names></name><name><surname>Papp</surname><given-names>B</given-names></name><name><surname>Pál</surname><given-names>C</given-names></name><name><surname>Csörgő</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Limited evolutionary conservation of the phenotypic effects of antibiotic resistance mutations</article-title><source>Molecular Biology and Evolution</source><volume>36</volume><fpage>1601</fpage><lpage>1611</lpage><pub-id pub-id-type="doi">10.1093/molbev/msz109</pub-id><pub-id pub-id-type="pmid">31058961</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldwin</surname><given-names>J</given-names></name><name><surname>Michnoff</surname><given-names>CH</given-names></name><name><surname>Malmquist</surname><given-names>NA</given-names></name><name><surname>White</surname><given-names>J</given-names></name><name><surname>Roth</surname><given-names>MG</given-names></name><name><surname>Rathod</surname><given-names>PK</given-names></name><name><surname>Phillips</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>High-throughput screening for potent and selective inhibitors of <italic>Plasmodium falciparum</italic> dihydroorotate dehydrogenase</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><fpage>21847</fpage><lpage>21853</lpage><pub-id pub-id-type="doi">10.1074/jbc.M501100200</pub-id><pub-id pub-id-type="pmid">15795226</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbosa</surname><given-names>C</given-names></name><name><surname>Römhild</surname><given-names>R</given-names></name><name><surname>Rosenstiel</surname><given-names>P</given-names></name><name><surname>Schulenburg</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Evolutionary stability of collateral sensitivity to antibiotics in the model pathogen <italic>Pseudomonas aeruginosa</italic></article-title><source>eLife</source><volume>8</volume><elocation-id>e51481</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.51481</pub-id><pub-id pub-id-type="pmid">31658946</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baym</surname><given-names>M</given-names></name><name><surname>Stone</surname><given-names>LK</given-names></name><name><surname>Kishony</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Multidrug evolutionary strategies to reverse antibiotic resistance</article-title><source>Science</source><volume>351</volume><elocation-id>aad3292</elocation-id><pub-id pub-id-type="doi">10.1126/science.aad3292</pub-id><pub-id pub-id-type="pmid">26722002</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodie</surname><given-names>M</given-names></name><name><surname>Gale-Rowe</surname><given-names>M</given-names></name><name><surname>Alexandre</surname><given-names>S</given-names></name><name><surname>Auguste</surname><given-names>U</given-names></name><name><surname>Tomas</surname><given-names>K</given-names></name><name><surname>Martin</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Addressing the rising rates of gonorrhea and drug-resistant gonorrhea: There is no time like the present</article-title><source>Canada Communicable Disease Report = Releve Des Maladies Transmissibles Au Canada</source><volume>45</volume><fpage>54</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.14745/ccdr.v45i23a02</pub-id><pub-id pub-id-type="pmid">31015819</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boni</surname><given-names>MF</given-names></name><name><surname>Smith</surname><given-names>DL</given-names></name><name><surname>Laxminarayan</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Benefits of using multiple first-line therapies against malaria</article-title><source>PNAS</source><volume>105</volume><fpage>14216</fpage><lpage>14221</lpage><pub-id pub-id-type="doi">10.1073/pnas.0804628105</pub-id><pub-id pub-id-type="pmid">18780786</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booker</surname><given-names>ML</given-names></name><name><surname>Bastos</surname><given-names>CM</given-names></name><name><surname>Kramer</surname><given-names>ML</given-names></name><name><surname>Barker</surname><given-names>RH</given-names></name><name><surname>Skerlj</surname><given-names>R</given-names></name><name><surname>Sidhu</surname><given-names>AB</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Celatka</surname><given-names>C</given-names></name><name><surname>Cortese</surname><given-names>JF</given-names></name><name><surname>Guerrero Bravo</surname><given-names>JE</given-names></name><name><surname>Crespo Llado</surname><given-names>KN</given-names></name><name><surname>Serrano</surname><given-names>AE</given-names></name><name><surname>Angulo-Barturen</surname><given-names>I</given-names></name><name><surname>Jiménez-Díaz</surname><given-names>MB</given-names></name><name><surname>Viera</surname><given-names>S</given-names></name><name><surname>Garuti</surname><given-names>H</given-names></name><name><surname>Wittlin</surname><given-names>S</given-names></name><name><surname>Papastogiannidis</surname><given-names>P</given-names></name><name><surname>Lin</surname><given-names>J-W</given-names></name><name><surname>Janse</surname><given-names>CJ</given-names></name><name><surname>Khan</surname><given-names>SM</given-names></name><name><surname>Duraisingh</surname><given-names>M</given-names></name><name><surname>Coleman</surname><given-names>B</given-names></name><name><surname>Goldsmith</surname><given-names>EJ</given-names></name><name><surname>Phillips</surname><given-names>MA</given-names></name><name><surname>Munoz</surname><given-names>B</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name><name><surname>Klinger</surname><given-names>JD</given-names></name><name><surname>Wiegand</surname><given-names>R</given-names></name><name><surname>Sybertz</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Novel inhibitors of <italic>Plasmodium falciparum</italic> dihydroorotate dehydrogenase with anti-malarial activity in the mouse model</article-title><source>The Journal of Biological Chemistry</source><volume>285</volume><fpage>33054</fpage><lpage>33064</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.162081</pub-id><pub-id pub-id-type="pmid">20702404</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bopp</surname><given-names>SER</given-names></name><name><surname>Manary</surname><given-names>MJ</given-names></name><name><surname>Bright</surname><given-names>AT</given-names></name><name><surname>Johnston</surname><given-names>GL</given-names></name><name><surname>Dharia</surname><given-names>NV</given-names></name><name><surname>Luna</surname><given-names>FL</given-names></name><name><surname>McCormack</surname><given-names>S</given-names></name><name><surname>Plouffe</surname><given-names>D</given-names></name><name><surname>McNamara</surname><given-names>CW</given-names></name><name><surname>Walker</surname><given-names>JR</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name><name><surname>Denchi</surname><given-names>EL</given-names></name><name><surname>Winzeler</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mitotic evolution of <italic>Plasmodium falciparum</italic> shows a stable core genome but recombination in antigen families</article-title><source>PLOS Genetics</source><volume>9</volume><elocation-id>e1003293</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1003293</pub-id><pub-id pub-id-type="pmid">23408914</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cihlar</surname><given-names>T</given-names></name><name><surname>Fordyce</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Current status and prospects of HIV treatment</article-title><source>Current Opinion in Virology</source><volume>18</volume><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2016.03.004</pub-id><pub-id pub-id-type="pmid">27023283</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coates</surname><given-names>ARM</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Holt</surname><given-names>J</given-names></name><name><surname>Yeh</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Antibiotic combination therapy against resistant bacterial infections: synergy, rejuvenation and resistance reduction</article-title><source>Expert Review of Anti-Infective Therapy</source><volume>18</volume><fpage>5</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1080/14787210.2020.1705155</pub-id><pub-id pub-id-type="pmid">31847614</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>RA</given-names></name><name><surname>Ferdig</surname><given-names>MT</given-names></name><name><surname>Su</surname><given-names>X-Z</given-names></name><name><surname>Ursos</surname><given-names>LMB</given-names></name><name><surname>Mu</surname><given-names>J</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Fujioka</surname><given-names>H</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name><name><surname>Roepe</surname><given-names>PD</given-names></name><name><surname>Wellems</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in <italic>Plasmodium falciparum</italic></article-title><source>Molecular Pharmacology</source><volume>61</volume><fpage>35</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1124/mol.61.1.35</pub-id><pub-id pub-id-type="pmid">11752204</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowell</surname><given-names>AN</given-names></name><name><surname>Istvan</surname><given-names>ES</given-names></name><name><surname>Lukens</surname><given-names>AK</given-names></name><name><surname>Gomez-Lorenzo</surname><given-names>MG</given-names></name><name><surname>Vanaerschot</surname><given-names>M</given-names></name><name><surname>Sakata-Kato</surname><given-names>T</given-names></name><name><surname>Flannery</surname><given-names>EL</given-names></name><name><surname>Magistrado</surname><given-names>P</given-names></name><name><surname>Owen</surname><given-names>E</given-names></name><name><surname>Abraham</surname><given-names>M</given-names></name><name><surname>LaMonte</surname><given-names>G</given-names></name><name><surname>Painter</surname><given-names>HJ</given-names></name><name><surname>Williams</surname><given-names>RM</given-names></name><name><surname>Franco</surname><given-names>V</given-names></name><name><surname>Linares</surname><given-names>M</given-names></name><name><surname>Arriaga</surname><given-names>I</given-names></name><name><surname>Bopp</surname><given-names>S</given-names></name><name><surname>Corey</surname><given-names>VC</given-names></name><name><surname>Gnädig</surname><given-names>NF</given-names></name><name><surname>Coburn-Flynn</surname><given-names>O</given-names></name><name><surname>Reimer</surname><given-names>C</given-names></name><name><surname>Gupta</surname><given-names>P</given-names></name><name><surname>Murithi</surname><given-names>JM</given-names></name><name><surname>Moura</surname><given-names>PA</given-names></name><name><surname>Fuchs</surname><given-names>O</given-names></name><name><surname>Sasaki</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Teng</surname><given-names>CH</given-names></name><name><surname>Wang</surname><given-names>LT</given-names></name><name><surname>Akidil</surname><given-names>A</given-names></name><name><surname>Adjalley</surname><given-names>S</given-names></name><name><surname>Willis</surname><given-names>PA</given-names></name><name><surname>Siegel</surname><given-names>D</given-names></name><name><surname>Tanaseichuk</surname><given-names>O</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Llinás</surname><given-names>M</given-names></name><name><surname>Ottilie</surname><given-names>S</given-names></name><name><surname>Gamo</surname><given-names>FJ</given-names></name><name><surname>Lee</surname><given-names>MCS</given-names></name><name><surname>Goldberg</surname><given-names>DE</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name><name><surname>Winzeler</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics</article-title><source>Science</source><volume>359</volume><fpage>191</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1126/science.aan4472</pub-id><pub-id pub-id-type="pmid">29326268</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dean</surname><given-names>Z</given-names></name><name><surname>Maltas</surname><given-names>J</given-names></name><name><surname>Wood</surname><given-names>KB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Antibiotic interactions shape short-term evolution of resistance in <italic>E. faecalis</italic></article-title><source>PLOS Pathogens</source><volume>16</volume><elocation-id>e1008278</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008278</pub-id><pub-id pub-id-type="pmid">32119717</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellus-Gur</surname><given-names>E</given-names></name><name><surname>Elias</surname><given-names>M</given-names></name><name><surname>Caselli</surname><given-names>E</given-names></name><name><surname>Prati</surname><given-names>F</given-names></name><name><surname>Salverda</surname><given-names>MLM</given-names></name><name><surname>de Visser</surname><given-names>J</given-names></name><name><surname>Fraser</surname><given-names>JS</given-names></name><name><surname>Tawfik</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Negative Epistasis and evolvability in TEM-1 β-Lactamase--The Thin line between an Enzyme’s Conformational Freedom and Disorder</article-title><source>Journal of Molecular Biology</source><volume>427</volume><fpage>2396</fpage><lpage>2409</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2015.05.011</pub-id><pub-id pub-id-type="pmid">26004540</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhawan</surname><given-names>A</given-names></name><name><surname>Nichol</surname><given-names>D</given-names></name><name><surname>Kinose</surname><given-names>F</given-names></name><name><surname>Abazeed</surname><given-names>ME</given-names></name><name><surname>Marusyk</surname><given-names>A</given-names></name><name><surname>Haura</surname><given-names>EB</given-names></name><name><surname>Scott</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>1232</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-00791-8</pub-id><pub-id pub-id-type="pmid">28450729</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dheda</surname><given-names>K</given-names></name><name><surname>Gumbo</surname><given-names>T</given-names></name><name><surname>Maartens</surname><given-names>G</given-names></name><name><surname>Dooley</surname><given-names>KE</given-names></name><name><surname>McNerney</surname><given-names>R</given-names></name><name><surname>Murray</surname><given-names>M</given-names></name><name><surname>Furin</surname><given-names>J</given-names></name><name><surname>Nardell</surname><given-names>EA</given-names></name><name><surname>London</surname><given-names>L</given-names></name><name><surname>Lessem</surname><given-names>E</given-names></name><name><surname>Theron</surname><given-names>G</given-names></name><name><surname>van Helden</surname><given-names>P</given-names></name><name><surname>Niemann</surname><given-names>S</given-names></name><name><surname>Merker</surname><given-names>M</given-names></name><name><surname>Dowdy</surname><given-names>D</given-names></name><name><surname>Van Rie</surname><given-names>A</given-names></name><name><surname>Siu</surname><given-names>GKH</given-names></name><name><surname>Pasipanodya</surname><given-names>JG</given-names></name><name><surname>Rodrigues</surname><given-names>C</given-names></name><name><surname>Clark</surname><given-names>TG</given-names></name><name><surname>Sirgel</surname><given-names>FA</given-names></name><name><surname>Esmail</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>H-H</given-names></name><name><surname>Atre</surname><given-names>SR</given-names></name><name><surname>Schaaf</surname><given-names>HS</given-names></name><name><surname>Chang</surname><given-names>KC</given-names></name><name><surname>Lange</surname><given-names>C</given-names></name><name><surname>Nahid</surname><given-names>P</given-names></name><name><surname>Udwadia</surname><given-names>ZF</given-names></name><name><surname>Horsburgh</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Churchyard</surname><given-names>GJ</given-names></name><name><surname>Menzies</surname><given-names>D</given-names></name><name><surname>Hesseling</surname><given-names>AC</given-names></name><name><surname>Nuermberger</surname><given-names>E</given-names></name><name><surname>McIlleron</surname><given-names>H</given-names></name><name><surname>Fennelly</surname><given-names>KP</given-names></name><name><surname>Goemaere</surname><given-names>E</given-names></name><name><surname>Jaramillo</surname><given-names>E</given-names></name><name><surname>Low</surname><given-names>M</given-names></name><name><surname>Jara</surname><given-names>CM</given-names></name><name><surname>Padayatchi</surname><given-names>N</given-names></name><name><surname>Warren</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis</article-title><source>The Lancet. Respiratory Medicine</source><volume>5</volume><fpage>291</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(17)30079-6</pub-id><pub-id pub-id-type="pmid">28344011</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>CK</given-names></name><name><surname>Urgaonkar</surname><given-names>S</given-names></name><name><surname>Cortese</surname><given-names>JF</given-names></name><name><surname>Gamo</surname><given-names>F-J</given-names></name><name><surname>Garcia-Bustos</surname><given-names>JF</given-names></name><name><surname>Lafuente</surname><given-names>MJ</given-names></name><name><surname>Patel</surname><given-names>V</given-names></name><name><surname>Ross</surname><given-names>L</given-names></name><name><surname>Coleman</surname><given-names>BI</given-names></name><name><surname>Derbyshire</surname><given-names>ER</given-names></name><name><surname>Clish</surname><given-names>CB</given-names></name><name><surname>Serrano</surname><given-names>AE</given-names></name><name><surname>Cromwell</surname><given-names>M</given-names></name><name><surname>Barker</surname><given-names>RH</given-names><suffix>Jr</suffix></name><name><surname>Dvorin</surname><given-names>JD</given-names></name><name><surname>Duraisingh</surname><given-names>MT</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name><name><surname>Clardy</surname><given-names>J</given-names></name><name><surname>Mazitschek</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Identification and validation of tetracyclic benzothiazepines as <italic>Plasmodium falciparum</italic> cytochrome bc1 inhibitors</article-title><source>Chemistry &amp; Biology</source><volume>18</volume><fpage>1602</fpage><lpage>1610</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2011.09.016</pub-id><pub-id pub-id-type="pmid">22195562</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffey</surname><given-names>M</given-names></name><name><surname>Blasco</surname><given-names>B</given-names></name><name><surname>Burrows</surname><given-names>JN</given-names></name><name><surname>Wells</surname><given-names>TNC</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name><name><surname>Leroy</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Assessing risks of <italic>Plasmodium falciparum</italic> resistance to select next-generation antimalarials</article-title><source>Trends in Parasitology</source><volume>37</volume><fpage>709</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2021.04.006</pub-id><pub-id pub-id-type="pmid">34001441</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>SG</given-names></name><name><surname>Havlik</surname><given-names>I</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title><italic>Plasmodium falciparum</italic>: effects of amantadine, an antiviral, on chloroquine-resistant and -sensitive parasites in vitro and its influence on chloroquine activity</article-title><source>Biochemical Pharmacology</source><volume>45</volume><fpage>1168</fpage><lpage>1170</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(93)90264-w</pub-id><pub-id pub-id-type="pmid">8461046</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flannery</surname><given-names>EL</given-names></name><name><surname>McNamara</surname><given-names>CW</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Kato</surname><given-names>TS</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Teng</surname><given-names>CH</given-names></name><name><surname>Gagaring</surname><given-names>K</given-names></name><name><surname>Manary</surname><given-names>MJ</given-names></name><name><surname>Barboa</surname><given-names>R</given-names></name><name><surname>Meister</surname><given-names>S</given-names></name><name><surname>Kuhen</surname><given-names>K</given-names></name><name><surname>Vinetz</surname><given-names>JM</given-names></name><name><surname>Chatterjee</surname><given-names>AK</given-names></name><name><surname>Winzeler</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials</article-title><source>ACS Chemical Biology</source><volume>10</volume><fpage>413</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1021/cb500616x</pub-id><pub-id pub-id-type="pmid">25322084</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>DE</given-names></name><name><surname>Siliciano</surname><given-names>RF</given-names></name><name><surname>Jacobs</surname><given-names>WR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Outwitting evolution: fighting drug-resistant TB, malaria, and HIV</article-title><source>Cell</source><volume>148</volume><fpage>1271</fpage><lpage>1283</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.02.021</pub-id><pub-id pub-id-type="pmid">22424234</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzales</surname><given-names>PR</given-names></name><name><surname>Pesesky</surname><given-names>MW</given-names></name><name><surname>Bouley</surname><given-names>R</given-names></name><name><surname>Ballard</surname><given-names>A</given-names></name><name><surname>Biddy</surname><given-names>BA</given-names></name><name><surname>Suckow</surname><given-names>MA</given-names></name><name><surname>Wolter</surname><given-names>WR</given-names></name><name><surname>Schroeder</surname><given-names>VA</given-names></name><name><surname>Burnham</surname><given-names>C-AD</given-names></name><name><surname>Mobashery</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Dantas</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Synergistic, collaterally sensitive β-lactam combinations suppress resistance in MRSA</article-title><source>Nature Chemical Biology</source><volume>11</volume><fpage>855</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1911</pub-id><pub-id pub-id-type="pmid">26368589</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregson</surname><given-names>J</given-names></name><name><surname>Kaleebu</surname><given-names>P</given-names></name><name><surname>Marconi</surname><given-names>VC</given-names></name><name><surname>van Vuuren</surname><given-names>C</given-names></name><name><surname>Ndembi</surname><given-names>N</given-names></name><name><surname>Hamers</surname><given-names>RL</given-names></name><name><surname>Kanki</surname><given-names>P</given-names></name><name><surname>Hoffmann</surname><given-names>CJ</given-names></name><name><surname>Lockman</surname><given-names>S</given-names></name><name><surname>Pillay</surname><given-names>D</given-names></name><name><surname>de Oliveira</surname><given-names>T</given-names></name><name><surname>Clumeck</surname><given-names>N</given-names></name><name><surname>Hunt</surname><given-names>G</given-names></name><name><surname>Kerschberger</surname><given-names>B</given-names></name><name><surname>Shafer</surname><given-names>RW</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Raizes</surname><given-names>E</given-names></name><name><surname>Kantor</surname><given-names>R</given-names></name><name><surname>Gupta</surname><given-names>RK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study</article-title><source>The Lancet Infectious Diseases</source><volume>17</volume><fpage>296</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(16)30469-8</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guler</surname><given-names>JL</given-names></name><name><surname>Freeman</surname><given-names>DL</given-names></name><name><surname>Ahyong</surname><given-names>V</given-names></name><name><surname>Patrapuvich</surname><given-names>R</given-names></name><name><surname>White</surname><given-names>J</given-names></name><name><surname>Gujjar</surname><given-names>R</given-names></name><name><surname>Phillips</surname><given-names>MA</given-names></name><name><surname>DeRisi</surname><given-names>J</given-names></name><name><surname>Rathod</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Asexual populations of the human malaria parasite, <italic>Plasmodium falciparum</italic>, use a two-step genomic strategy to acquire accurate, beneficial DNA amplifications</article-title><source>PLOS Pathogens</source><volume>9</volume><elocation-id>e1003375</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003375</pub-id><pub-id pub-id-type="pmid">23717205</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haldar</surname><given-names>K</given-names></name><name><surname>Bhattacharjee</surname><given-names>S</given-names></name><name><surname>Safeukui</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Drug resistance in Plasmodium</article-title><source>Nature Reviews. Microbiology</source><volume>16</volume><fpage>156</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2017.161</pub-id><pub-id pub-id-type="pmid">29355852</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>WL</given-names></name><name><surname>Amato</surname><given-names>R</given-names></name><name><surname>van der Pluijm</surname><given-names>RW</given-names></name><name><surname>Jacob</surname><given-names>CG</given-names></name><name><surname>Quang</surname><given-names>HH</given-names></name><name><surname>Thuy-Nhien</surname><given-names>NT</given-names></name><name><surname>Hien</surname><given-names>TT</given-names></name><name><surname>Hongvanthong</surname><given-names>B</given-names></name><name><surname>Chindavongsa</surname><given-names>K</given-names></name><name><surname>Mayxay</surname><given-names>M</given-names></name><name><surname>Huy</surname><given-names>R</given-names></name><name><surname>Leang</surname><given-names>R</given-names></name><name><surname>Huch</surname><given-names>C</given-names></name><name><surname>Dysoley</surname><given-names>L</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Suon</surname><given-names>S</given-names></name><name><surname>Fairhurst</surname><given-names>RM</given-names></name><name><surname>Tripura</surname><given-names>R</given-names></name><name><surname>Peto</surname><given-names>TJ</given-names></name><name><surname>Sovann</surname><given-names>Y</given-names></name><name><surname>Jittamala</surname><given-names>P</given-names></name><name><surname>Hanboonkunupakarn</surname><given-names>B</given-names></name><name><surname>Pukrittayakamee</surname><given-names>S</given-names></name><name><surname>Chau</surname><given-names>NH</given-names></name><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>Vongpromek</surname><given-names>R</given-names></name><name><surname>Chan</surname><given-names>XHS</given-names></name><name><surname>Maude</surname><given-names>RJ</given-names></name><name><surname>Pearson</surname><given-names>RD</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Rockett</surname><given-names>K</given-names></name><name><surname>Drury</surname><given-names>E</given-names></name><name><surname>Gonçalves</surname><given-names>S</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Day</surname><given-names>NP</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Miotto</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study</article-title><source>The Lancet. Infectious Diseases</source><volume>19</volume><fpage>943</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(19)30392-5</pub-id><pub-id pub-id-type="pmid">31345709</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hastings</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance</article-title><source>Trends in Parasitology</source><volume>27</volume><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2010.09.005</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hegreness</surname><given-names>M</given-names></name><name><surname>Shoresh</surname><given-names>N</given-names></name><name><surname>Damian</surname><given-names>D</given-names></name><name><surname>Hartl</surname><given-names>D</given-names></name><name><surname>Kishony</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Accelerated evolution of resistance in multidrug environments</article-title><source>PNAS</source><volume>105</volume><fpage>13977</fpage><lpage>13981</lpage><pub-id pub-id-type="doi">10.1073/pnas.0805965105</pub-id><pub-id pub-id-type="pmid">18779569</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huijben</surname><given-names>S</given-names></name><name><surname>Paaijmans</surname><given-names>KP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Putting evolution in elimination: Winning our ongoing battle with evolving malaria mosquitoes and parasites</article-title><source>Evolutionary Applications</source><volume>11</volume><fpage>415</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1111/eva.12530</pub-id><pub-id pub-id-type="pmid">29636796</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imamovic</surname><given-names>L</given-names></name><name><surname>Sommer</surname><given-names>MOA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development</article-title><source>Science Translational Medicine</source><volume>5</volume><elocation-id>204ra132</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3006609</pub-id><pub-id pub-id-type="pmid">24068739</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jee</surname><given-names>Y</given-names></name><name><surname>Carlson</surname><given-names>J</given-names></name><name><surname>Rafai</surname><given-names>E</given-names></name><name><surname>Musonda</surname><given-names>K</given-names></name><name><surname>Huong</surname><given-names>TTG</given-names></name><name><surname>Daza</surname><given-names>P</given-names></name><name><surname>Sattayawuthipong</surname><given-names>W</given-names></name><name><surname>Yoon</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Antimicrobial resistance: a threat to global health</article-title><source>The Lancet. Infectious Diseases</source><volume>18</volume><fpage>939</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30471-7</pub-id><pub-id pub-id-type="pmid">30152350</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>YJ</given-names></name><name><surname>Baym</surname><given-names>M</given-names></name><name><surname>Veres</surname><given-names>A</given-names></name><name><surname>Kishony</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Population Diversity Jeopardizes the Efficacy of Antibiotic Cycling</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/082107</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>DJ</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name><name><surname>Mungthin</surname><given-names>M</given-names></name><name><surname>Lakshmanan</surname><given-names>V</given-names></name><name><surname>Sidhu</surname><given-names>ABS</given-names></name><name><surname>Bray</surname><given-names>PG</given-names></name><name><surname>Ward</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Evidence for a central role for PfCRT in conferring <italic>Plasmodium falciparum</italic> resistance to diverse antimalarial agents</article-title><source>Molecular Cell</source><volume>15</volume><fpage>867</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2004.09.012</pub-id><pub-id pub-id-type="pmid">15383277</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>JD</given-names></name><name><surname>Dennull</surname><given-names>RA</given-names></name><name><surname>Gerena</surname><given-names>L</given-names></name><name><surname>Lopez-Sanchez</surname><given-names>M</given-names></name><name><surname>Roncal</surname><given-names>NE</given-names></name><name><surname>Waters</surname><given-names>NC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Assessment and continued validation of the Malaria SYBR Green I-Based Fluorescence Assay for use in Malaria Drug Screening</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>51</volume><fpage>1926</fpage><lpage>1933</lpage><pub-id pub-id-type="doi">10.1128/AAC.01607-06</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerantzas</surname><given-names>CA</given-names></name><name><surname>Jacobs</surname><given-names>WR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Origins of combination Therapy for Tuberculosis: lessons for future antimicrobial development and application</article-title><source>mBio</source><volume>8</volume><elocation-id>e01586-16</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.01586-16</pub-id><pub-id pub-id-type="pmid">28292983</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Lieberman</surname><given-names>TD</given-names></name><name><surname>Kishony</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance</article-title><source>PNAS</source><volume>111</volume><fpage>14494</fpage><lpage>14499</lpage><pub-id pub-id-type="doi">10.1073/pnas.1409800111</pub-id><pub-id pub-id-type="pmid">25246554</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirkman</surname><given-names>LA</given-names></name><name><surname>Zhan</surname><given-names>W</given-names></name><name><surname>Visone</surname><given-names>J</given-names></name><name><surname>Dziedziech</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>PK</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Tong</surname><given-names>X</given-names></name><name><surname>Bruzual</surname><given-names>I</given-names></name><name><surname>Hara</surname><given-names>R</given-names></name><name><surname>Kawasaki</surname><given-names>M</given-names></name><name><surname>Imaeda</surname><given-names>T</given-names></name><name><surname>Okamoto</surname><given-names>R</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Michino</surname><given-names>M</given-names></name><name><surname>Alvaro</surname><given-names>EF</given-names></name><name><surname>Guiang</surname><given-names>LF</given-names></name><name><surname>Sanz</surname><given-names>L</given-names></name><name><surname>Mota</surname><given-names>DJ</given-names></name><name><surname>Govindasamy</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Ling</surname><given-names>Y</given-names></name><name><surname>Tumwebaze</surname><given-names>PK</given-names></name><name><surname>Sukenick</surname><given-names>G</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Vendome</surname><given-names>J</given-names></name><name><surname>Bhanot</surname><given-names>P</given-names></name><name><surname>Rosenthal</surname><given-names>PJ</given-names></name><name><surname>Aso</surname><given-names>K</given-names></name><name><surname>Foley</surname><given-names>MA</given-names></name><name><surname>Cooper</surname><given-names>RA</given-names></name><name><surname>Kafsack</surname><given-names>B</given-names></name><name><surname>Doggett</surname><given-names>JS</given-names></name><name><surname>Nathan</surname><given-names>CF</given-names></name><name><surname>Lin</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance</article-title><source>PNAS</source><volume>115</volume><fpage>E6863</fpage><lpage>E6870</lpage><pub-id pub-id-type="doi">10.1073/pnas.1806109115</pub-id><pub-id pub-id-type="pmid">29967165</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambros</surname><given-names>C</given-names></name><name><surname>Vanderberg</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="1979">1979</year><article-title>Synchronization of <italic>Plasmodium falciparum</italic> erythrocytic stages in culture</article-title><source>The Journal of Parasitology</source><volume>65</volume><fpage>418</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">383936</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leroux</surname><given-names>P</given-names></name><name><surname>Chapeland</surname><given-names>F</given-names></name><name><surname>Arnold</surname><given-names>A</given-names></name><name><surname>Gredt</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>New cases of negative cross-resistance between Fungicides, including Sterol Biosynthesis inhibitors</article-title><source>Journal of General Plant Pathology</source><volume>66</volume><fpage>75</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1007/PL00012925</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llanos-Cuentas</surname><given-names>A</given-names></name><name><surname>Casapia</surname><given-names>M</given-names></name><name><surname>Chuquiyauri</surname><given-names>R</given-names></name><name><surname>Hinojosa</surname><given-names>J-C</given-names></name><name><surname>Kerr</surname><given-names>N</given-names></name><name><surname>Rosario</surname><given-names>M</given-names></name><name><surname>Toovey</surname><given-names>S</given-names></name><name><surname>Arch</surname><given-names>RH</given-names></name><name><surname>Phillips</surname><given-names>MA</given-names></name><name><surname>Rozenberg</surname><given-names>FD</given-names></name><name><surname>Bath</surname><given-names>J</given-names></name><name><surname>Ng</surname><given-names>CL</given-names></name><name><surname>Cowell</surname><given-names>AN</given-names></name><name><surname>Winzeler</surname><given-names>EA</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Möhrle</surname><given-names>JJ</given-names></name><name><surname>Hooft van Huijsduijnen</surname><given-names>R</given-names></name><name><surname>Gobeau</surname><given-names>N</given-names></name><name><surname>Araeipour</surname><given-names>N</given-names></name><name><surname>Andenmatten</surname><given-names>N</given-names></name><name><surname>Rückle</surname><given-names>T</given-names></name><name><surname>Duparc</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated <italic>Plasmodium falciparum</italic> or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study</article-title><source>The Lancet. Infectious Diseases</source><volume>18</volume><fpage>874</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30309-8</pub-id><pub-id pub-id-type="pmid">29909069</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorendeau</surname><given-names>D</given-names></name><name><surname>Dury</surname><given-names>L</given-names></name><name><surname>Nasr</surname><given-names>R</given-names></name><name><surname>Boumendjel</surname><given-names>A</given-names></name><name><surname>Teodori</surname><given-names>E</given-names></name><name><surname>Gutschow</surname><given-names>M</given-names></name><name><surname>Falson</surname><given-names>P</given-names></name><name><surname>Di Pietro</surname><given-names>A</given-names></name><name><surname>Baubichon-Cortay</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MRP1-dependent Collateral sensitivity of multidrug-resistant Cancer Cells: identifying selective modulators inducing cellular Glutathione depletion</article-title><source>Current Medicinal Chemistry</source><volume>24</volume><fpage>1186</fpage><lpage>1213</lpage><pub-id pub-id-type="doi">10.2174/0929867324666161118130238</pub-id><pub-id pub-id-type="pmid">27855620</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lozovsky</surname><given-names>ER</given-names></name><name><surname>Chookajorn</surname><given-names>T</given-names></name><name><surname>Brown</surname><given-names>KM</given-names></name><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>Shaw</surname><given-names>PJ</given-names></name><name><surname>Kamchonwongpaisan</surname><given-names>S</given-names></name><name><surname>Neafsey</surname><given-names>DE</given-names></name><name><surname>Weinreich</surname><given-names>DM</given-names></name><name><surname>Hartl</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Stepwise acquisition of pyrimethamine resistance in the malaria parasite</article-title><source>PNAS</source><volume>106</volume><fpage>12025</fpage><lpage>12030</lpage><pub-id pub-id-type="doi">10.1073/pnas.0905922106</pub-id><pub-id pub-id-type="pmid">19587242</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukens</surname><given-names>AK</given-names></name><name><surname>Ross</surname><given-names>LS</given-names></name><name><surname>Heidebrecht</surname><given-names>R</given-names></name><name><surname>Javier Gamo</surname><given-names>F</given-names></name><name><surname>Lafuente-Monasterio</surname><given-names>MJ</given-names></name><name><surname>Booker</surname><given-names>ML</given-names></name><name><surname>Hartl</surname><given-names>DL</given-names></name><name><surname>Wiegand</surname><given-names>RC</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Harnessing evolutionary fitness in <italic>Plasmodium falciparum</italic> for drug discovery and suppressing resistance</article-title><source>PNAS</source><volume>111</volume><fpage>799</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1073/pnas.1320886110</pub-id><pub-id pub-id-type="pmid">24381157</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukens</surname><given-names>AK</given-names></name><name><surname>Heidebrecht</surname><given-names>RW</given-names><suffix>Jr</suffix></name><name><surname>Mulrooney</surname><given-names>C</given-names></name><name><surname>Beaudoin</surname><given-names>JA</given-names></name><name><surname>Comer</surname><given-names>E</given-names></name><name><surname>Duvall</surname><given-names>JR</given-names></name><name><surname>Fitzgerald</surname><given-names>ME</given-names></name><name><surname>Masi</surname><given-names>D</given-names></name><name><surname>Galinsky</surname><given-names>K</given-names></name><name><surname>Scherer</surname><given-names>CA</given-names></name><name><surname>Palmer</surname><given-names>M</given-names></name><name><surname>Munoz</surname><given-names>B</given-names></name><name><surname>Foley</surname><given-names>M</given-names></name><name><surname>Schreiber</surname><given-names>SL</given-names></name><name><surname>Wiegand</surname><given-names>RC</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Diversity-oriented synthesis probe targets <italic>Plasmodium falciparum</italic> cytochrome b ubiquinone reduction site and synergizes with oxidation site inhibitors</article-title><source>The Journal of Infectious Diseases</source><volume>211</volume><fpage>1097</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu565</pub-id><pub-id pub-id-type="pmid">25336726</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maltas</surname><given-names>J</given-names></name><name><surname>Wood</surname><given-names>KB</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pervasive and diverse collateral sensitivity profiles inform optimal strategies to limit antibiotic resistance</article-title><source>PLOS Biology</source><volume>17</volume><elocation-id>e3000515</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3000515</pub-id><pub-id pub-id-type="pmid">31652256</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manary</surname><given-names>MJ</given-names></name><name><surname>Singhakul</surname><given-names>SS</given-names></name><name><surname>Flannery</surname><given-names>EL</given-names></name><name><surname>Bopp</surname><given-names>SE</given-names></name><name><surname>Corey</surname><given-names>VC</given-names></name><name><surname>Bright</surname><given-names>AT</given-names></name><name><surname>McNamara</surname><given-names>CW</given-names></name><name><surname>Walker</surname><given-names>JR</given-names></name><name><surname>Winzeler</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Identification of pathogen genomic variants through an integrated pipeline</article-title><source>BMC Bioinformatics</source><volume>15</volume><elocation-id>63</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-15-63</pub-id><pub-id pub-id-type="pmid">24589256</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandt</surname><given-names>REK</given-names></name><name><surname>Lafuente-Monasterio</surname><given-names>MJ</given-names></name><name><surname>Sakata-Kato</surname><given-names>T</given-names></name><name><surname>Luth</surname><given-names>MR</given-names></name><name><surname>Segura</surname><given-names>D</given-names></name><name><surname>Pablos-Tanarro</surname><given-names>A</given-names></name><name><surname>Viera</surname><given-names>S</given-names></name><name><surname>Magan</surname><given-names>N</given-names></name><name><surname>Ottilie</surname><given-names>S</given-names></name><name><surname>Winzeler</surname><given-names>EA</given-names></name><name><surname>Lukens</surname><given-names>AK</given-names></name><name><surname>Gamo</surname><given-names>FJ</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model</article-title><source>Science Translational Medicine</source><volume>11</volume><elocation-id>eaav1636</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aav1636</pub-id><pub-id pub-id-type="pmid">31801884</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manson</surname><given-names>AL</given-names></name><name><surname>Cohen</surname><given-names>KA</given-names></name><name><surname>Abeel</surname><given-names>T</given-names></name><name><surname>Desjardins</surname><given-names>CA</given-names></name><name><surname>Armstrong</surname><given-names>DT</given-names></name><name><surname>Barry</surname><given-names>CE</given-names></name><name><surname>Brand</surname><given-names>J</given-names></name><collab>TBResist Global Genome Consortium</collab><name><surname>Chapman</surname><given-names>SB</given-names></name><name><surname>Cho</surname><given-names>SN</given-names></name><name><surname>Gabrielian</surname><given-names>A</given-names></name><name><surname>Gomez</surname><given-names>J</given-names></name><name><surname>Jodals</surname><given-names>AM</given-names></name><name><surname>Joloba</surname><given-names>M</given-names></name><name><surname>Jureen</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Malinga</surname><given-names>L</given-names></name><name><surname>Maiga</surname><given-names>M</given-names></name><name><surname>Nordenberg</surname><given-names>D</given-names></name><name><surname>Noroc</surname><given-names>E</given-names></name><name><surname>Romancenco</surname><given-names>E</given-names></name><name><surname>Salazar</surname><given-names>A</given-names></name><name><surname>Ssengooba</surname><given-names>W</given-names></name><name><surname>Velayati</surname><given-names>AA</given-names></name><name><surname>Winglee</surname><given-names>K</given-names></name><name><surname>Zalutskaya</surname><given-names>A</given-names></name><name><surname>Via</surname><given-names>LE</given-names></name><name><surname>Cassell</surname><given-names>GH</given-names></name><name><surname>Dorman</surname><given-names>SE</given-names></name><name><surname>Ellner</surname><given-names>J</given-names></name><name><surname>Farnia</surname><given-names>P</given-names></name><name><surname>Galagan</surname><given-names>JE</given-names></name><name><surname>Rosenthal</surname><given-names>A</given-names></name><name><surname>Crudu</surname><given-names>V</given-names></name><name><surname>Homorodean</surname><given-names>D</given-names></name><name><surname>Hsueh</surname><given-names>PR</given-names></name><name><surname>Narayanan</surname><given-names>S</given-names></name><name><surname>Pym</surname><given-names>AS</given-names></name><name><surname>Skrahina</surname><given-names>A</given-names></name><name><surname>Swaminathan</surname><given-names>S</given-names></name><name><surname>Van der Walt</surname><given-names>M</given-names></name><name><surname>Alland</surname><given-names>D</given-names></name><name><surname>Bishai</surname><given-names>WR</given-names></name><name><surname>Cohen</surname><given-names>T</given-names></name><name><surname>Hoffner</surname><given-names>S</given-names></name><name><surname>Birren</surname><given-names>BW</given-names></name><name><surname>Earl</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance</article-title><source>Nature Genetics</source><volume>49</volume><fpage>395</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1038/ng.3767</pub-id><pub-id pub-id-type="pmid">28092681</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>JS</given-names></name><name><surname>Lotharius</surname><given-names>J</given-names></name><name><surname>Rückle</surname><given-names>T</given-names></name><name><surname>Chalon</surname><given-names>S</given-names></name><name><surname>Phillips</surname><given-names>MA</given-names></name><name><surname>Elliott</surname><given-names>S</given-names></name><name><surname>Sekuloski</surname><given-names>S</given-names></name><name><surname>Griffin</surname><given-names>P</given-names></name><name><surname>Ng</surname><given-names>CL</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name><name><surname>Marquart</surname><given-names>L</given-names></name><name><surname>Williams</surname><given-names>NS</given-names></name><name><surname>Gobeau</surname><given-names>N</given-names></name><name><surname>Bebrevska</surname><given-names>L</given-names></name><name><surname>Rosario</surname><given-names>M</given-names></name><name><surname>Marsh</surname><given-names>K</given-names></name><name><surname>Möhrle</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study</article-title><source>The Lancet. Infectious Diseases</source><volume>17</volume><fpage>626</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30171-8</pub-id><pub-id pub-id-type="pmid">28363636</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munck</surname><given-names>C</given-names></name><name><surname>Gumpert</surname><given-names>HK</given-names></name><name><surname>Wallin</surname><given-names>AIN</given-names></name><name><surname>Wang</surname><given-names>HH</given-names></name><name><surname>Sommer</surname><given-names>MOA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Prediction of resistance development against drug combinations by collateral responses to component drugs</article-title><source>Science Translational Medicine</source><volume>6</volume><elocation-id>262ra156</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3009940</pub-id><pub-id pub-id-type="pmid">25391482</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>SC</given-names></name><name><surname>Duke</surname><given-names>ER</given-names></name><name><surname>Shipman</surname><given-names>KJ</given-names></name><name><surname>Jensen</surname><given-names>RL</given-names></name><name><surname>Fong</surname><given-names>Y</given-names></name><name><surname>Ferguson</surname><given-names>S</given-names></name><name><surname>Janes</surname><given-names>HE</given-names></name><name><surname>Gillespie</surname><given-names>K</given-names></name><name><surname>Seilie</surname><given-names>AM</given-names></name><name><surname>Hanron</surname><given-names>AE</given-names></name><name><surname>Rinn</surname><given-names>L</given-names></name><name><surname>Fishbaugher</surname><given-names>M</given-names></name><name><surname>VonGoedert</surname><given-names>T</given-names></name><name><surname>Fritzen</surname><given-names>E</given-names></name><name><surname>Kappe</surname><given-names>SH</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Sousa</surname><given-names>JC</given-names></name><name><surname>Marcsisin</surname><given-names>SR</given-names></name><name><surname>Chalon</surname><given-names>S</given-names></name><name><surname>Duparc</surname><given-names>S</given-names></name><name><surname>Kerr</surname><given-names>N</given-names></name><name><surname>Möhrle</surname><given-names>JJ</given-names></name><name><surname>Andenmatten</surname><given-names>N</given-names></name><name><surname>Rueckle</surname><given-names>T</given-names></name><name><surname>Kublin</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A randomized trial evaluating the prophylactic activity of DSM265 against preerythrocytic <italic>Plasmodium falciparum</italic> infection during controlled Human Malarial Infection by Mosquito Bites and Direct Venous Inoculation</article-title><source>The Journal of Infectious Diseases</source><volume>217</volume><fpage>693</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1093/infdis/jix613</pub-id><pub-id pub-id-type="pmid">29216395</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichol</surname><given-names>D</given-names></name><name><surname>Rutter</surname><given-names>J</given-names></name><name><surname>Bryant</surname><given-names>C</given-names></name><name><surname>Hujer</surname><given-names>AM</given-names></name><name><surname>Lek</surname><given-names>S</given-names></name><name><surname>Adams</surname><given-names>MD</given-names></name><name><surname>Jeavons</surname><given-names>P</given-names></name><name><surname>Anderson</surname><given-names>ARA</given-names></name><name><surname>Bonomo</surname><given-names>RA</given-names></name><name><surname>Scott</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Antibiotic collateral sensitivity is contingent on the repeatability of evolution</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>334</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-08098-6</pub-id><pub-id pub-id-type="pmid">30659188</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Painter</surname><given-names>HJ</given-names></name><name><surname>Morrisey</surname><given-names>JM</given-names></name><name><surname>Mather</surname><given-names>MW</given-names></name><name><surname>Vaidya</surname><given-names>AB</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Specific role of mitochondrial electron transport in blood-stage <italic>Plasmodium falciparum</italic></article-title><source>Nature</source><volume>446</volume><fpage>88</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1038/nature05572</pub-id><pub-id pub-id-type="pmid">17330044</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>V</given-names></name><name><surname>Booker</surname><given-names>M</given-names></name><name><surname>Kramer</surname><given-names>M</given-names></name><name><surname>Ross</surname><given-names>L</given-names></name><name><surname>Celatka</surname><given-names>CA</given-names></name><name><surname>Kennedy</surname><given-names>LM</given-names></name><name><surname>Dvorin</surname><given-names>JD</given-names></name><name><surname>Duraisingh</surname><given-names>MT</given-names></name><name><surname>Sliz</surname><given-names>P</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name><name><surname>Clardy</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Identification and characterization of small molecule inhibitors of <italic>Plasmodium falciparum</italic> dihydroorotate dehydrogenase</article-title><source>Journal of Biological Chemistry</source><volume>283</volume><fpage>35078</fpage><lpage>35085</lpage><pub-id pub-id-type="doi">10.1074/jbc.M804990200</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavadai</surname><given-names>E</given-names></name><name><surname>El Mazouni</surname><given-names>F</given-names></name><name><surname>Wittlin</surname><given-names>S</given-names></name><name><surname>de Kock</surname><given-names>C</given-names></name><name><surname>Phillips</surname><given-names>MA</given-names></name><name><surname>Chibale</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Identification of New Human Malaria Parasite <italic>Plasmodium falciparum</italic> dihydroorotate dehydrogenase inhibitors by Pharmacophore and structure-based virtual screening</article-title><source>Journal of Chemical Information and Modeling</source><volume>56</volume><fpage>548</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.5b00680</pub-id><pub-id pub-id-type="pmid">26915022</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>MA</given-names></name><name><surname>Gujjar</surname><given-names>R</given-names></name><name><surname>Malmquist</surname><given-names>NA</given-names></name><name><surname>White</surname><given-names>J</given-names></name><name><surname>El Mazouni</surname><given-names>F</given-names></name><name><surname>Baldwin</surname><given-names>J</given-names></name><name><surname>Rathod</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite <italic>Plasmodium falciparum</italic></article-title><source>Journal of Medicinal Chemistry</source><volume>51</volume><fpage>3649</fpage><lpage>3653</lpage><pub-id pub-id-type="doi">10.1021/jm8001026</pub-id><pub-id pub-id-type="pmid">18522386</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>MA</given-names></name><name><surname>Rathod</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy</article-title><source>Infectious Disorders Drug Targets</source><volume>10</volume><fpage>226</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.2174/187152610791163336</pub-id><pub-id pub-id-type="pmid">20334617</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>MA</given-names></name><name><surname>Lotharius</surname><given-names>J</given-names></name><name><surname>Marsh</surname><given-names>K</given-names></name><name><surname>White</surname><given-names>J</given-names></name><name><surname>Dayan</surname><given-names>A</given-names></name><name><surname>White</surname><given-names>KL</given-names></name><name><surname>Njoroge</surname><given-names>JW</given-names></name><name><surname>El Mazouni</surname><given-names>F</given-names></name><name><surname>Lao</surname><given-names>Y</given-names></name><name><surname>Kokkonda</surname><given-names>S</given-names></name><name><surname>Tomchick</surname><given-names>DR</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Laird</surname><given-names>T</given-names></name><name><surname>Bhatia</surname><given-names>SN</given-names></name><name><surname>March</surname><given-names>S</given-names></name><name><surname>Ng</surname><given-names>CL</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name><name><surname>Wittlin</surname><given-names>S</given-names></name><name><surname>Lafuente-Monasterio</surname><given-names>M</given-names></name><name><surname>Benito</surname><given-names>FJG</given-names></name><name><surname>Alonso</surname><given-names>LMS</given-names></name><name><surname>Martinez</surname><given-names>MS</given-names></name><name><surname>Jimenez-Diaz</surname><given-names>MB</given-names></name><name><surname>Bazaga</surname><given-names>SF</given-names></name><name><surname>Angulo-Barturen</surname><given-names>I</given-names></name><name><surname>Haselden</surname><given-names>JN</given-names></name><name><surname>Louttit</surname><given-names>J</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Sridhar</surname><given-names>A</given-names></name><name><surname>Zeeman</surname><given-names>A-M</given-names></name><name><surname>Kocken</surname><given-names>C</given-names></name><name><surname>Sauerwein</surname><given-names>R</given-names></name><name><surname>Dechering</surname><given-names>K</given-names></name><name><surname>Avery</surname><given-names>VM</given-names></name><name><surname>Duffy</surname><given-names>S</given-names></name><name><surname>Delves</surname><given-names>M</given-names></name><name><surname>Sinden</surname><given-names>R</given-names></name><name><surname>Ruecker</surname><given-names>A</given-names></name><name><surname>Wickham</surname><given-names>KS</given-names></name><name><surname>Rochford</surname><given-names>R</given-names></name><name><surname>Gahagen</surname><given-names>J</given-names></name><name><surname>Iyer</surname><given-names>L</given-names></name><name><surname>Riccio</surname><given-names>E</given-names></name><name><surname>Mirsalis</surname><given-names>J</given-names></name><name><surname>Bathhurst</surname><given-names>I</given-names></name><name><surname>Rueckle</surname><given-names>T</given-names></name><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Campo</surname><given-names>B</given-names></name><name><surname>Leroy</surname><given-names>D</given-names></name><name><surname>Rogers</surname><given-names>MJ</given-names></name><name><surname>Rathod</surname><given-names>PK</given-names></name><name><surname>Burrows</surname><given-names>JN</given-names></name><name><surname>Charman</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria</article-title><source>Science Translational Medicine</source><volume>7</volume><elocation-id>296ra111</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaa6645</pub-id><pub-id pub-id-type="pmid">26180101</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rank</surname><given-names>GH</given-names></name><name><surname>Robertson</surname><given-names>AJ</given-names></name><name><surname>Phillips</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="1975">1975</year><article-title>Modification and inheritance of pleiotropic cross resistance and collateral sensitivity in <italic>Saccharomyces cerevisiae</italic></article-title><source>Genetics</source><volume>80</volume><fpage>783</fpage><lpage>793</lpage><pub-id pub-id-type="pmid">782999</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>SN</given-names></name><name><surname>Nash</surname><given-names>MN</given-names></name><name><surname>Baker</surname><given-names>ES</given-names></name><name><surname>Webster</surname><given-names>MW</given-names></name><name><surname>Lehane</surname><given-names>AM</given-names></name><name><surname>Shafik</surname><given-names>SH</given-names></name><name><surname>Martin</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Molecular Mechanisms for Drug Hypersensitivity induced by the Malaria Parasite’s Chloroquine Resistance Transporter</article-title><source>PLOS Pathogens</source><volume>12</volume><elocation-id>e1005725</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005725</pub-id><pub-id pub-id-type="pmid">27441371</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez de Evgrafov</surname><given-names>M</given-names></name><name><surname>Gumpert</surname><given-names>H</given-names></name><name><surname>Munck</surname><given-names>C</given-names></name><name><surname>Thomsen</surname><given-names>TT</given-names></name><name><surname>Sommer</surname><given-names>MOA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Collateral resistance and sensitivity modulate evolution of high-level resistance to Drug Combination Treatment in <italic>Staphylococcus aureus</italic></article-title><source>Molecular Biology and Evolution</source><volume>32</volume><fpage>1175</fpage><lpage>1185</lpage><pub-id pub-id-type="doi">10.1093/molbev/msv006</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenkilde</surname><given-names>CEH</given-names></name><name><surname>Munck</surname><given-names>C</given-names></name><name><surname>Porse</surname><given-names>A</given-names></name><name><surname>Linkevicius</surname><given-names>M</given-names></name><name><surname>Andersson</surname><given-names>DI</given-names></name><name><surname>Sommer</surname><given-names>MOA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Collateral sensitivity constrains resistance evolution of the CTX-M-15 β-lactamase</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>618</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-08529-y</pub-id><pub-id pub-id-type="pmid">30728359</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>LS</given-names></name><name><surname>Gamo</surname><given-names>FJ</given-names></name><name><surname>Lafuente-Monasterio</surname><given-names>MJ</given-names></name><name><surname>Singh</surname><given-names>OMP</given-names></name><name><surname>Rowland</surname><given-names>P</given-names></name><name><surname>Wiegand</surname><given-names>RC</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>In vitro resistance selections for <italic>Plasmodium falciparum</italic> dihydroorotate dehydrogenase inhibitors give mutants with multiple point mutations in the drug-binding site and altered growth</article-title><source>The Journal of Biological Chemistry</source><volume>289</volume><fpage>17980</fpage><lpage>17995</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.558353</pub-id><pub-id pub-id-type="pmid">24782313</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>LS</given-names></name><name><surname>Lafuente-Monasterio</surname><given-names>MJ</given-names></name><name><surname>Sakata-Kato</surname><given-names>T</given-names></name><name><surname>Mandt</surname><given-names>REK</given-names></name><name><surname>Gamo</surname><given-names>FJ</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name><name><surname>Lukens</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Identification of collateral sensitivity to dihydroorotate dehydrogenase inhibitors in <italic>Plasmodium falciparum</italic></article-title><source>ACS Infectious Diseases</source><volume>4</volume><fpage>508</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.7b00217</pub-id><pub-id pub-id-type="pmid">29336544</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>A</given-names></name><name><surname>Wolfensberger</surname><given-names>A</given-names></name><name><surname>Nemeth</surname><given-names>J</given-names></name><name><surname>Schreiber</surname><given-names>PW</given-names></name><name><surname>Sax</surname><given-names>H</given-names></name><name><surname>Kuster</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: Systematic Review and Meta-Analysis</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>15290</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-51711-x</pub-id><pub-id pub-id-type="pmid">31664064</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sisowath</surname><given-names>C</given-names></name><name><surname>Petersen</surname><given-names>I</given-names></name><name><surname>Veiga</surname><given-names>MI</given-names></name><name><surname>Mårtensson</surname><given-names>A</given-names></name><name><surname>Premji</surname><given-names>Z</given-names></name><name><surname>Björkman</surname><given-names>A</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name><name><surname>Gil</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>In vivo selection of <italic>Plasmodium falciparum</italic> parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa</article-title><source>The Journal of Infectious Diseases</source><volume>199</volume><fpage>750</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1086/596738</pub-id><pub-id pub-id-type="pmid">19210165</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Small-Saunders</surname><given-names>JL</given-names></name><name><surname>Hagenah</surname><given-names>LM</given-names></name><name><surname>Wicht</surname><given-names>KJ</given-names></name><name><surname>Dhingra</surname><given-names>SK</given-names></name><name><surname>Deni</surname><given-names>I</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Vendome</surname><given-names>J</given-names></name><name><surname>Gil-Iturbe</surname><given-names>E</given-names></name><name><surname>Roepe</surname><given-names>PD</given-names></name><name><surname>Mehta</surname><given-names>M</given-names></name><name><surname>Mancia</surname><given-names>F</given-names></name><name><surname>Quick</surname><given-names>M</given-names></name><name><surname>Eppstein</surname><given-names>MJ</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Evidence for the early emergence of piperaquine-resistant <italic>Plasmodium falciparum</italic> malaria and modeling strategies to mitigate resistance</article-title><source>PLOS Pathogens</source><volume>18</volume><elocation-id>e1010278</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1010278</pub-id><pub-id pub-id-type="pmid">35130315</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smilkstein</surname><given-names>M</given-names></name><name><surname>Sriwilaijaroen</surname><given-names>N</given-names></name><name><surname>Kelly</surname><given-names>JX</given-names></name><name><surname>Wilairat</surname><given-names>P</given-names></name><name><surname>Riscoe</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>48</volume><fpage>1803</fpage><lpage>1806</lpage><pub-id pub-id-type="doi">10.1128/AAC.48.5.1803-1806.2004</pub-id><pub-id pub-id-type="pmid">15105138</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stokes</surname><given-names>BH</given-names></name><name><surname>Yoo</surname><given-names>E</given-names></name><name><surname>Murithi</surname><given-names>JM</given-names></name><name><surname>Luth</surname><given-names>MR</given-names></name><name><surname>Afanasyev</surname><given-names>P</given-names></name><name><surname>da Fonseca</surname><given-names>PCA</given-names></name><name><surname>Winzeler</surname><given-names>EA</given-names></name><name><surname>Ng</surname><given-names>CL</given-names></name><name><surname>Bogyo</surname><given-names>M</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Covalent <italic>Plasmodium falciparum</italic>-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents</article-title><source>PLOS Pathogens</source><volume>15</volume><elocation-id>e1007722</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1007722</pub-id><pub-id pub-id-type="pmid">31170268</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sulyok</surname><given-names>M</given-names></name><name><surname>Rückle</surname><given-names>T</given-names></name><name><surname>Roth</surname><given-names>A</given-names></name><name><surname>Mürbeth</surname><given-names>RE</given-names></name><name><surname>Chalon</surname><given-names>S</given-names></name><name><surname>Kerr</surname><given-names>N</given-names></name><name><surname>Samec</surname><given-names>SS</given-names></name><name><surname>Gobeau</surname><given-names>N</given-names></name><name><surname>Calle</surname><given-names>CL</given-names></name><name><surname>Ibáñez</surname><given-names>J</given-names></name><name><surname>Sulyok</surname><given-names>Z</given-names></name><name><surname>Held</surname><given-names>J</given-names></name><name><surname>Gebru</surname><given-names>T</given-names></name><name><surname>Granados</surname><given-names>P</given-names></name><name><surname>Brückner</surname><given-names>S</given-names></name><name><surname>Nguetse</surname><given-names>C</given-names></name><name><surname>Mengue</surname><given-names>J</given-names></name><name><surname>Lalremruata</surname><given-names>A</given-names></name><name><surname>Sim</surname><given-names>BKL</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name><name><surname>Möhrle</surname><given-names>JJ</given-names></name><name><surname>Kremsner</surname><given-names>PG</given-names></name><name><surname>Mordmüller</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>DSM265 for <italic>Plasmodium falciparum</italic> chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection</article-title><source>The Lancet. Infectious Diseases</source><volume>17</volume><fpage>636</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30139-1</pub-id><pub-id pub-id-type="pmid">28363637</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>J</given-names></name><name><surname>Dhingra</surname><given-names>SK</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>El Mazouni</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>MCS</given-names></name><name><surname>Afanador</surname><given-names>GA</given-names></name><name><surname>Lawong</surname><given-names>A</given-names></name><name><surname>Tomchick</surname><given-names>DR</given-names></name><name><surname>Ng</surname><given-names>CL</given-names></name><name><surname>Bath</surname><given-names>J</given-names></name><name><surname>Rathod</surname><given-names>PK</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name><name><surname>Phillips</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Identification and mechanistic understanding of dihydroorotate dehydrogenase point mutations in <italic>Plasmodium falciparum</italic> that confer in vitro resistance to the Clinical Candidate DSM265</article-title><source>ACS Infectious Diseases</source><volume>5</volume><fpage>90</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.8b00211</pub-id><pub-id pub-id-type="pmid">30375858</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom"><italic>dhodh; Pfdhodh</italic></td><td align="left" valign="bottom">PlasmoDB</td><td align="left" valign="bottom">PF3D7_0603300</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Plasmodium falciparum</italic>)</td><td align="char" char="." valign="bottom">3D7 A10</td><td align="left" valign="bottom">Goldberg lab at Washington University, St. Louis, MO, USA</td><td align="left" valign="bottom">3D7 A10; 3D7_A10</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib12">Cowell et al., 2018</xref></td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">T-F1-C1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of 3D7 A10 parasites with TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">T-F1-C2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of 3D7 A10 parasites with TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">T-F1-C3</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of 3D7 A10 parasites with TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">T-F2-C1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of 3D7 A10 parasites with TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">T-F2-C2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of 3D7 A10 parasites with TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">T-F2-C3</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of 3D7 A10 parasites with TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">T-F2-C4</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of 3D7 A10 parasites with TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">T-F2-C5</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of 3D7 A10 parasites with TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">C276Y Parent</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib47">Mandt et al., 2019</xref></td><td align="left" valign="bottom">S1-F1-C1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">D-T-F1-C1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of C276Y parent parasites with TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">D-T-F1-C2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of C276Y parent parasites with TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">D-T-F1-C3</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of C276Y parent parasites with TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">D-T-F1-C4</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of C276Y parent parasites with TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">D-T-F2-C1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of C276Y parent parasites with TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">D-T-F2-C2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of C276Y parent parasites with TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">D-T-F2-C3</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of C276Y parent parasites with TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">D-T-F2-C4</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of C276Y parent parasites with TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">D-T-F3-C1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of C276Y parent parasites with TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">D-T-F3-C2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of C276Y parent parasites with TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">D-T-F3-C3</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of C276Y parent parasites with TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">DT-F1-C1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of 3D7 A10 parasites with DSM265 and TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">DT-F1-C2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of 3D7 A10 parasites with DSM265 and TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">DT-F1-C3</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of 3D7 A10 parasites with DSM265 and TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">DT-F1-C4</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of 3D7 A10 parasites with DSM265 and TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">DT-F2-C1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of 3D7 A10 parasites with DSM265 and TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">DT-F2-C2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of 3D7 A10 parasites with DSM265 and TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">DT-F2-C3</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of 3D7 A10 parasites with DSM265 and TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">DT-F2-C4</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of 3D7 A10 parasites with DSM265 and TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">DT-F2-C5</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of 3D7 A10 parasites with DSM265 and TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Plasmodium falciparum</italic>)</td><td align="left" valign="bottom">DT-F2-C6</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated from selection of 3D7 A10 parasites with DSM265 and TCMDC-125334; available upon request</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DHODH F1A</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib47">Mandt et al., 2019</xref></td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">GTGTGATAGATAGCTCCAGTCG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DHODH R1B</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib47">Mandt et al., 2019</xref></td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">CGTTTGGCCCCTTGGGGTTATGG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DHODH F2A</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib47">Mandt et al., 2019</xref></td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">TTGATGGTGAAATATGTCATGACCTT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DHODH R2A</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib47">Mandt et al., 2019</xref></td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">CCAAGGGCTTCTTTTTTGTTGTATTAAACC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DHODH F3A</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib47">Mandt et al., 2019</xref></td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">GTCACATGATGAAAGATGCTAAGG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DHODH R3B</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib47">Mandt et al., 2019</xref></td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">CGCACTTATGTGTCGCCCG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DHODH Front-F</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib24">Guler et al., 2013</xref></td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">TCCATTCGGTGTTGCTGCAGGATTTGAT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DHODH Front-R</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib24">Guler et al., 2013</xref></td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">TCTGTAACTTTGTCACAACCCATATTA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DHODH Rear-F</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib24">Guler et al., 2013</xref></td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">GTGTTAGCGGAGCAAAACTAAAAG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DHODH Rear-R</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib24">Guler et al., 2013</xref></td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">ATAATTGACAAACTGAAGCACCTG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Seryl t-RNA Synthetase-F</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib24">Guler et al., 2013</xref></td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">GGAACAATTCTGTATTGCTTTACC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Seryl t-RNA Synthetase-R</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib24">Guler et al., 2013</xref></td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">AAGCTGCGTTGTTTAAAGCTC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">18s Ribosomal RNA</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib24">Guler et al., 2013</xref></td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">ACAATTCATCATATCTTTCAATCGGTA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">18s Ribosomal RNA</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib24">Guler et al., 2013</xref></td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">GCTGACTACGTCCCTGCCC</named-content></td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Nextera XT DNA Library Preparation Kit</td><td align="left" valign="bottom">Illumina</td><td align="left" valign="bottom">Cat # FC-131–1024</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">DNeasy Blood &amp; Tissue Kit</td><td align="left" valign="bottom">QIAGEN</td><td align="left" valign="bottom">Cat # 69556</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">LookOut Mycoplasma PCR Detection Kit</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat # MP0035</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Phusion High-Fidelity PCR Master Mix</td><td align="left" valign="bottom">New England BioLabs</td><td align="left" valign="bottom">Cat No: M0531S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">DNA/RNA Shield</td><td align="left" valign="bottom">Zymo Research</td><td align="left" valign="bottom">Cat No: R1200-25</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">SYBR Green Master Mix</td><td align="left" valign="bottom">Applied Biosystems</td><td align="left" valign="bottom">Cat No: A46109</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">IDI-6273</td><td align="left" valign="bottom">ChemDiv</td><td align="left" valign="bottom">ChemDiv4861-0080</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Genz669178</td><td align="left" valign="bottom">Genzyme, a Sanofi Company</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DSM265</td><td align="left" valign="bottom">Laboratory of Margaret Phillips, University of Texas Southwestern, Dallas, TX, USA</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib58">Phillips et al., 2015</xref></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Atovaquone</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">CAS No: 95233-18-4; Product No: A7986</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dihydroartemisinin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">CAS No: 71939-50-9; Product No: 1200520</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">TCMDC-125334</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib64">Ross et al., 2018</xref></td><td align="left" valign="bottom">Additional material ordered from MolPort: MolPort-004-150-355</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">HaplotypeCaller</td><td align="left" valign="bottom">Genome Analysis Toolkit (GATK)</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See also: <xref ref-type="bibr" rid="bib12">Cowell et al., 2018</xref></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Platypus pipeline</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://sourceforge.net/projects/platypusmga/">https://sourceforge.net/projects/platypusmga/</ext-link><break/>; <xref ref-type="bibr" rid="bib46">Manary et al., 2014</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">See also: <xref ref-type="bibr" rid="bib12">Cowell et al., 2018</xref></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom"><italic>Plasmodium</italic> CNV analysis pipeline</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://bitbucket.org/rwillia2001/plasmodium_cnv_analysis/src/master/">rwillia2001 /</ext-link><ext-link ext-link-type="uri" xlink:href="https://bitbucket.org/rwillia2001/plasmodium_cnv_analysis/src/master/">plasmodium</ext-link><ext-link ext-link-type="uri" xlink:href="https://bitbucket.org/rwillia2001/plasmodium_cnv_analysis/src/master/">_cnv_analysis — Bitbucket</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib12">Cowell et al., 2018</xref></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Prism v9</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">CDD Vault</td><td align="left" valign="bottom">Collaborative Drug Discovery Inc.</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">MultiExperimentViewer (MeV) version 4.9.0</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://sourceforge.net/projects/mev-tm4/">https://sourceforge.net/projects/mev-tm4/</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Applied Biosystems QuantStudio Real-Time PCR Software</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Flare v.4.0.3.40719</td><td align="left" valign="bottom">Cresset-GroupTM</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">PyMOL v. 4.6.0</td><td align="left" valign="bottom">Intel</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85023.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Clayton</surname><given-names>Christine</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Centre for Molecular Biology of Heidelberg University (ZMBH), retired</institution><country>Germany</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.04.07.486819" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.04.07.486819"/></front-stub><body><p>This study addresses an important question in the field of antimicrobial chemotherapy: whether combinations of enzyme inhibitors that select for mutations that confer resistance to one inhibitor and at the same time increased sensitization to the other inhibitor, can provide a path towards mitigating resistance risks. The authors investigated one such combination of inhibitors of <italic>Plasmodium falciparum</italic> DHODH (dihydroorotate dehydrogenase), finding that despite &quot;collateral sensitivity&quot;, it was still possible to select parasites with resistance to both inhibitors without any change in parasite fitness. Additional cross-susceptibility and structural modelling strengthen this study, which is performed to a high technical standard and presents a convincing body of data.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85023.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Clayton</surname><given-names>Christine</given-names></name><role>Reviewing Editor</role><aff><institution>Centre for Molecular Biology of Heidelberg University (ZMBH), retired</institution><country>Germany</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Clayton</surname><given-names>Christine</given-names></name><role>Reviewer</role><aff><institution>Centre for Molecular Biology of Heidelberg University (ZMBH), retired</institution><country>Germany</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.04.07.486819">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.04.07.486819v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Collateral sensitivity as a strategy to suppress resistance emergence: the challenge of diverse evolutionary pathways&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Christine Clayton as Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Dominique Soldati-Favre as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>a) In summarizing and in the discussion, please make it clear that the detailed results concern only one pair of inhibitors. Remove unsupported broad generalizations (or else, say that they are possible interpretations but would need to be confirmed with additional compound combinations). Mention copy-number variation in the Abstract.</p><p>b) Figure 3 panel E – please provide EC50s also for the measurements currently labelled as &quot;&gt;&quot;, as requested by reviewer 2.</p><p>c) The variation in font sizes in the Figures is unacceptable. Please use similar font sizes for all labels in all Figures. Everything must be easy to read at 100% on a laptop. Also please implement other suggestions concerning the intelligibility of the Figures, such as colour choices.</p><p>d) In tables, reduce the number of significant figures to reflect the accuracy of the data.</p><p>e) In all Figures/tables, describe what the statistical test was, how many replicates there were, and how they were obtained (how many independent experiments).</p><p>f) To completely understand the development of double resistance (and particularly, how serious a problem it would be) it would be necessary to measure the frequency of double resistance emergence compared with using either compound alone. Please state this clearly as a caveat to your results. You could also, for the 10<sup>8</sup> inoculum, explicitly compare the times to obtain resistance both compounds and to each individual compound.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Sweeping general statements, such as &quot;if a resistant mutant is competitively fit, treatment with a second drug will more likely result in the acquisition of additional genetic changes and subsequent multi-drug resistance&quot; – while plausible – are not supported by the data. To make such a statement it would be necessary to test multiple different resistance mutations, and several different inhibitors and targets.</p><p>The combination of the two drugs resulted in a delay in the generation of resistance, but no quantitation is provided. Also, different selection protocols were used in the various experiments. What is the frequency of resistance emergence compared with using either compound alone? This is important.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Below are a number of suggestions for ways to improve the manuscript. Most relate to data presentation or the text. There is also one request to repeat some drug assays with DSM265 shown in Figure 3E to ensure that the IC50 values are accurately captured.</p><p>– In the Introduction, the authors should provide a broader overview of the function of DHODH. Later, when discussing their selection studies (typically conducted with ~10<sup>8</sup> parasites) they should discuss how this aligns with prior studies that have selected for resistance and reported the minimum inoculum of resistance (MIR) values for this target (stated as log10 = 5.5 in PMID 34001441).</p><p>– Page 4 para 2: References 36-41 do not all refer to PfCRT. I would recommend removing 36 and 41 and replacing them with PMID 35130315</p><p>– Please spell out the abbreviation FMN (flavin mononucleotide).</p><p>– Figure 1 is an excellent way of presenting how mutations impact compound potency in terms of cross-resistance or collateral susceptibility. Panel B should relabel the text on the right, which is currently in poor resolution. The legend should also clarify – was this always the same parental line for each mutant? Panel C should indicate this is a log10 scale (on the panel and also the legend). Minor ticks should be used to add more resolution to the Y axes (e.g. placed between the 0 and log10 values of 2 or -2, which equates to 100-fold higher or lower values). Also, given that panels B and C are presumably the same parasite data, why does it extend to log10 values of 2 or -2 in C and only 1 or -1 in B? Please clarify.</p><p>– Starting on page 7, the authors state: &quot;Of the clones isolated from flask 2, four did not have a resistance phenotype, and had no genetic changes in the dhodh locus (Figure 2C-F, Table 1, Figure S2)&quot;. The authors should indicate that Figure 2 illustrates only one clone, F2-C2, with no CNV or SNP in DHODH and no change in IC50. There is only one other clone shown, which is F2-C1 which has an I263S mutation. Do the authors ascribe this to the removal of drug pressure during the expansion of these clones?</p><p>– For Table 1, I would recommend reducing the number of significant digits to 1 for values below 10 nM (for example, writing 5.1 nM, not 5.07 nM). This would be more in line with the accuracy of these data. The same applies (less often) to Tables 2-4 and Figure S3B (note: there is no &quot;A&quot; listed in Figure S3).</p><p>– Figure 3: Panel E has highly unconventional labeling with &quot;&gt;values shown&quot;. The legend indicates that &quot;In cases where the EC50 could not be determined with a range of concentrations tested, the maximum concentration that achieved &gt;50% growth was used as a stand-in value.&quot;. These are intermediate values that should be entirely feasible to measure. Rather than setting this new standard, the authors should repeat enough assays to provide accurate mean {plus minus} SD values. Also, the authors should review each panel and add sufficient minor ticks to allow readers to estimate values. Panel G also has a labeling error – the green dose-response line should be C276Y/F227Y (not C276Y as is also shown for the blue line). Also, the legend needs improvement. in vitro dose needs italics only for in vitro and not for dose. The legend also states &quot;th DHODH C276Y/F227Y&quot;. The legend also states that the F227Y mutant was selected using DSM265, yet the next textual paragraph below shows that this mutant was selected using DSM267. Which is it?</p><p>– Figure 3 (more): This legend also shows that the dose-response data showed SDs of technical replicates. The legend should clarify whether this means independent assays or technical replicates of a single assay. Data File S1 shows that these are mostly three independent bio-reps with 3D7-A10 having 12-13. The legend should refer to this Data file, as should the legends of all Figures that show data outlined in that file.</p><p>– The qPCR data refer to DHODH front or DHODH rear. Please define these terms.</p><p>– Figure 4C: The X axis should read DSM265 not DSM-265.</p><p>– Figure S2 legend: Please specify the type of error bar and numbers of bio-reps and technical replicates. Also, please specify what is meant by DHODH front vs rear. Finally, it would likely be better to tailor each Y axis to the data sets shown in each panel, rather than having several panels show the data only represented at the bottom of the graph. Please be sure to place enough tick marks to allow the reader to more easily estimate relative copy numbers. Also, please explain in the legend why Flask 2 from Round 1 was not used in Round 2.</p><p>– Page 17: Please correct &quot;by the calculating&quot;.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>1. Since the study &quot;brings into question the usefulness of pursuing further DHODH inhibitors&quot;, I wonder if the authors could develop their thinking further on this important point.</p><p>a. Would deep mutational scanning be useful here, for example?</p><p>b. Is the view here that those previously tested combinations would indeed also fail if pressured further for cross-resistance?</p><p>c. Do the authors believe that CNV could be a general mechanism that would undermine other collateral resistance strategies?</p><p>d. Is the broader conclusion here that it would be advisable to combine drugs against two (or more) independent targets rather than using two drugs against one target?</p><p>2. Could the authors clarify the relationship between the compound screen reported in 2018 (ref 47) and the compound screen reported in Figure 1B here? Is there any overlap? Compound 17 looks to have been a promising potential candidate for combination follow-up in the prior study.</p><p>3. I'm assuming that no 'non-DHODH' mutations were detected by whole-genome sequencing, but I'm not sure if this is stated in the manuscript. This is important as the genotype, and resistance phenotype relationships are not validated by gene editing, for example.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85023.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>a) In summarizing and in the discussion, please make it clear that the detailed results concern only one pair of inhibitors. Remove unsupported broad generalizations (or else, say that they are possible interpretations but would need to be confirmed with additional compound combinations). Mention copy-number variation in the Abstract.</p></disp-quote><p>We have revised the Discussion section to focus on one pair of inhibitors. We have also noted in the abstract that copy-number variation was a common mechanism of resistance to TCMDC-125334.</p><disp-quote content-type="editor-comment"><p>b) Figure 3 panel E – please provide EC50s also for the measurements currently labelled as &quot;&gt;&quot;, as requested by reviewer 2.</p></disp-quote><p>We have conducted additional drug assays with adjusted dose ranges that have allowed us to accurately calculate EC­<sub>50</sub> values for Figure 3.</p><disp-quote content-type="editor-comment"><p>c) The variation in font sizes in the Figures is unacceptable. Please use similar font sizes for all labels in all Figures. Everything must be easy to read at 100% on a laptop. Also please implement other suggestions concerning the intelligibility of the Figures, such as colour choices.</p></disp-quote><p>We have increased and standardized the font size across all figures and made other requested changes to the figures.</p><disp-quote content-type="editor-comment"><p>d) In tables, reduce the number of significant figures to reflect the accuracy of the data.</p></disp-quote><p>We have reduced the number of significant figures in the tables based on Reviewer #2’s recommendations.</p><disp-quote content-type="editor-comment"><p>e) In all Figures/tables, describe what the statistical test was, how many replicates there were, and how they were obtained (how many independent experiments).</p></disp-quote><p>We have included additional information in the figure legends to describe the statistical test and replicates.</p><disp-quote content-type="editor-comment"><p>f) To completely understand the development of double resistance (and particularly, how serious a problem it would be) it would be necessary to measure the frequency of double resistance emergence compared with using either compound alone. Please state this clearly as a caveat to your results. You could also, for the 10<sup>8</sup> inoculum, explicitly compare the times to obtain resistance both compounds and to each individual compound.</p></disp-quote><p>We have noted this in the Discussion section. See paragraph starting with: “We cannot quantify the frequency of resistance emergence based on our results…”</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Sweeping general statements, such as &quot;if a resistant mutant is competitively fit, treatment with a second drug will more likely result in the acquisition of additional genetic changes and subsequent multi-drug resistance&quot; – while plausible – are not supported by the data. To make such a statement it would be necessary to test multiple different resistance mutations, and several different inhibitors and targets.</p></disp-quote><p>We have edited the Discussion section per the reviewer’s suggestion.</p><disp-quote content-type="editor-comment"><p>The combination of the two drugs resulted in a delay in the generation of resistance, but no quantitation is provided. Also, different selection protocols were used in the various experiments. What is the frequency of resistance emergence compared with using either compound alone? This is important.</p></disp-quote><p>We do quantify the days to resistance emergence in the figures. This comparison is now described directly in the text. We also note the number of flasks in which resistance parasites emerge, but given that we are only using three populations per selection experiment, we cannot draw a conclusion about the frequency of resistance emergence based on our results. Doing so would require a Luria-Delbruck type experimental design that is beyond the scope of this study. We have provided information on the hematocrit, the starting inoculates, and the time to resistance.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Below are a number of suggestions for ways to improve the manuscript. Most relate to data presentation or the text. There is also one request to repeat some drug assays with DSM265 shown in Figure 3E to ensure that the IC50 values are accurately captured.</p><p>– In the Introduction, the authors should provide a broader overview of the function of DHODH. Later, when discussing their selection studies (typically conducted with ~10<sup>8</sup> parasites) they should discuss how this aligns with prior studies that have selected for resistance and reported the minimum inoculum of resistance (MIR) values for this target (stated as log10 = 5.5 in PMID 34001441).</p></disp-quote><p>We have added additional context about DHODH to the introduction. We also noted in the Results section that the MIR for DSM265 is 10<sup>5.5</sup>.</p><disp-quote content-type="editor-comment"><p>– Page 4 para 2: References 36-41 do not all refer to PfCRT. I would recommend removing 36 and 41 and replacing them with PMID 35130315</p></disp-quote><p>We have added the indicated reference.</p><disp-quote content-type="editor-comment"><p>– Please spell out the abbreviation FMN (flavin mononucleotide).</p></disp-quote><p>We have spelled out the first use of the abbreviation FMN.</p><disp-quote content-type="editor-comment"><p>– Figure 1 is an excellent way of presenting how mutations impact compound potency in terms of cross-resistance or collateral susceptibility. Panel B should relabel the text on the right, which is currently in poor resolution. The legend should also clarify – was this always the same parental line for each mutant? Panel C should indicate this is a log10 scale (on the panel and also the legend). Minor ticks should be used to add more resolution to the Y axes (e.g. placed between the 0 and log10 values of 2 or -2, which equates to 100-fold higher or lower values). Also, given that panels B and C are presumably the same parasite data, why does it extend to log10 values of 2 or -2 in C and only 1 or -1 in B? Please clarify.</p></disp-quote><p>We have relabeled the text in Panel B and added information about the parental lines for each mutant. We have also indicated the axis is log10 scale, and added minor ticks to the Y-axes for panel C. We appreciate the reviewer’s observation about the range of the data in Panel B vs. Panel C. We have changed the scale in the heatmap in Panel B to log10=-2 to log10=2.</p><disp-quote content-type="editor-comment"><p>– Starting on page 7, the authors state: &quot;Of the clones isolated from flask 2, four did not have a resistance phenotype, and had no genetic changes in the dhodh locus (Figure 2C-F, Table 1, Figure S2)&quot;. The authors should indicate that Figure 2 illustrates only one clone, F2-C2, with no CNV or SNP in DHODH and no change in IC50.</p></disp-quote><p>We note in the figure legend that the figure only shows two representative clones from each flask. The complete set of clones is described in Table 1. We have added an additional sentence to the text for each figure clarifying this.</p><disp-quote content-type="editor-comment"><p>There is only one other clone shown, which is F2-C1 which has an I263S mutation. Do the authors ascribe this to the removal of drug pressure during the expansion of these clones?</p></disp-quote><p>This is an interesting question. Our interpretation is that in the bulk culture there were both mutant and wildtype parasites. We did not examine the fitness of the DHODH I263S mutant line in the absence of drug.</p><disp-quote content-type="editor-comment"><p>– For Table 1, I would recommend reducing the number of significant digits to 1 for values below 10 nM (for example, writing 5.1 nM, not 5.07 nM). This would be more in line with the accuracy of these data. The same applies (less often) to Tables 2-4 and Figure S3B (note: there is no &quot;A&quot; listed in Figure S3).</p></disp-quote><p>We have adjusted the significant figures of the data per the reviewer’s recommendations.</p><disp-quote content-type="editor-comment"><p>– Figure 3: Panel E has highly unconventional labeling with &quot;&gt;values shown&quot;. The legend indicates that &quot;In cases where the EC50 could not be determined with a range of concentrations tested, the maximum concentration that achieved &gt;50% growth was used as a stand-in value.&quot;. These are intermediate values that should be entirely feasible to measure. Rather than setting this new standard, the authors should repeat enough assays to provide accurate mean {plus minus} SD values. Also, the authors should review each panel and add sufficient minor ticks to allow readers to estimate values. Panel G also has a labeling error – the green dose-response line should be C276Y/F227Y (not C276Y as is also shown for the blue line). Also, the legend needs improvement. in vitro dose needs italics only for in vitro and not for dose. The legend also states &quot;th DHODH C276Y/F227Y&quot;. The legend also states that the F227Y mutant was selected using DSM265, yet the next textual paragraph below shows that this mutant was selected using DSM267. Which is it?</p></disp-quote><p>We have conducted additional drug assays with adjusted dose ranges that have allowed us to accurately calculate EC­<sub>50</sub> values for Figure 3. We have also made the corrections to the figure labels and legends.</p><disp-quote content-type="editor-comment"><p>– Figure 3 (more): This legend also shows that the dose-response data showed SDs of technical replicates. The legend should clarify whether this means independent assays or technical replicates of a single assay. Data File S1 shows that these are mostly three independent bio-reps with 3D7-A10 having 12-13. The legend should refer to this Data file, as should the legends of all Figures that show data outlined in that file.</p></disp-quote><p>We have clarified that these are technical replicates of a single representative dose response assay. We also now refer to the tables and supplemental data files in the figure legends.</p><disp-quote content-type="editor-comment"><p>– The qPCR data refer to DHODH front or DHODH rear. Please define these terms.</p></disp-quote><p>We have clarified that DHODH front and DHODH rear refer to two amplicons within the DHODH gene.</p><disp-quote content-type="editor-comment"><p>– Figure 4C: The X axis should read DSM265 not DSM-265.</p></disp-quote><p>We have corrected the axis.</p><disp-quote content-type="editor-comment"><p>– Figure S2 legend: Please specify the type of error bar and numbers of bio-reps and technical replicates. Also, please specify what is meant by DHODH front vs rear. Finally, it would likely be better to tailor each Y axis to the data sets shown in each panel, rather than having several panels show the data only represented at the bottom of the graph. Please be sure to place enough tick marks to allow the reader to more easily estimate relative copy numbers. Also, please explain in the legend why Flask 2 from Round 1 was not used in Round 2.</p></disp-quote><p>We have updated the legend to note that DHODH front and DHODH rear refer to two amplicons within the dhodh gene. We have also added information about the technical replicates and error bars. We also adjusted the axes in the figures per the reviewer’s recommendation.</p><disp-quote content-type="editor-comment"><p>– Page 17: Please correct &quot;by the calculating&quot;.</p></disp-quote><p>We have fixed this typo.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>1. Since the study &quot;brings into question the usefulness of pursuing further DHODH inhibitors&quot;, I wonder if the authors could develop their thinking further on this important point.</p><p>a. Would deep mutational scanning be useful here, for example?</p><p>b. Is the view here that those previously tested combinations would indeed also fail if pressured further for cross-resistance?</p><p>c. Do the authors believe that CNV could be a general mechanism that would undermine other collateral resistance strategies?</p><p>d. Is the broader conclusion here that it would be advisable to combine drugs against two (or more) independent targets rather than using two drugs against one target?</p></disp-quote><p>We have expanded on this thinking in the discussion.</p><disp-quote content-type="editor-comment"><p>2. Could the authors clarify the relationship between the compound screen reported in 2018 (ref 47) and the compound screen reported in Figure 1B here? Is there any overlap? Compound 17 looks to have been a promising potential candidate for combination follow-up in the prior study.</p></disp-quote><p>We have clarified this relationship when discussing the results for Figure 1B. Compound 17 from the 2018 high-throughput screen is TCMDC-125334.</p><disp-quote content-type="editor-comment"><p>3. I'm assuming that no 'non-DHODH' mutations were detected by whole-genome sequencing, but I'm not sure if this is stated in the manuscript. This is important as the genotype, and resistance phenotype relationships are not validated by gene editing, for example.</p></disp-quote><p>There were additional mutations outside the dhodh locus identified via whole-genome sequencing. Based on the mutation rate and time in culture we expect a certain amount of variation to occur (see PMID:23408914). However, we found no instances of variation outside of DHODH appearing in multiple independent selections. We have noted this in the Discussion section. We are also making the whole genome sequence data publicly available.</p></body></sub-article></article>